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ABSTRACT 
 
INTRODUCTION 
The focus of this MD thesis has been relaxin, a member of the insulin family, 
which is a protein composed of two disulphide linked chains of approximately 
6000 Daltons.   Relaxin has been traditionally recognised as a hormone of 
parturition, though more recently it has been postulated that relaxin may be 
involved in cardiovascular regulation. We used concentrations similar to those 
found in the plasma in physiological (non-pregnant, pregnancy) and 
pathophysiological (chronic heart failure) states. Firstly, we characterised the 
effects of relaxin in small human resistance arteries ex vivo using wire myography 
obtained from gluteal biopsies taken from patients with coronary heart disease 
(CHD) and normal left ventricular systolic function.  We also studied the same 
effects in larger calibre arteries (internal mammary) and veins (saphenous) using 
standard organ bath techniques.  The effect of relaxin in veins has not previously 
been described. Internal mammary arteries and saphenous veins were obtained 
from patients undergoing coronary artery bypass surgery. Small pulmonary arteries 
were obtained from patients undergoing thoracotomy for bronchial carcinoma. In 
addition, we wished to determine if a transcardiac or transpulmonary gradient of 
relaxin could be measured to suggest either pulmonary or cardiac secretion or 
clearance of the hormone. Relaxin secretion in heart failure has previously been 
described. Lastly, we wished to determine whether an increased relaxin plasma 
concentration in patients with chronic heart failure (CHF), is of prognostic 
importance. 
 
METHODS AND RESULTS 
i)comparative potency of relaxin compared to other vasodilators:  Small resistance 
arteries were obtained from biopsies taken from patients with CHD. Each set of 
vessels was preconstricted with noradrenaline. Thereafter, cumulative concentration 
response (relaxation) curves (CRCs) were constructed with known vasodilators 
 25 
atrial natriuretic peptide (ANP), epoprostenol, substance P and relaxin (n=8). 
Relaxin was found to be a more potent vasodilator than ANP and equipotent to 
epoprostenol.  
ii) mechanism of vasorelaxation: CRCs to relaxin (as above) were constructed to 
identify the importance of the endothelium – following the removal of the 
endothelium by the established method of intraluminal rubbing with a human hair. 
We found that relaxin is endothelium dependent.  
iii) interaction of relaxin with nitric oxide and other possible mechanisms of 
vasodilation and importance of ACE inhibitor treatment: We identified the 
importance of the effect of ACE inhibitor treatment on the action of relaxin in 
human resistance arteries. Relaxin’s vasodilatory action was significantly reduced 
in those patients on ACE inhibitors (n=28) compared with those patients not on 
ACE inhibitors (n=30). In patients treated with an ACE inhibitor, we found that 
manipulation of prostanoids is important. Indomethacin, (a cyclooxygenase 
inhibitor) (n=8) blocked relaxin’s vasodilatory action. Manipulation of the cAMP 
second messenger system, with milrinone, (a cAMP phosphodiesterase inhibitor) 
(n=6) is also important as relaxin’s vasodilatory action was enhanced. Manipulation 
of cyclic GMP second messenger system is also important. ODQ, (a guanylate 
cyclase inhibitor) (n=10) reduced relaxin’s action while zaprinast, (a cGMP 
phosphodiesterase inhibitor) (n=7) enhanced relaxin’s action.  Manipulation of 
nitric oxide with L-NAME (n=8) and L-NOARG (n=10), nitric oxide synthase 
(NOS) inhibitors and EDHF with apamin and charybdotoxin (potassium channel 
blockers) (n=7) had a curious effect causing the opposite action to that expected, by 
enhancing relaxin’s vasodilatory action. In patients not treated with an ACE 
inhibitor, we found that manipulation of nitric oxide with L-NAME (n=8) and L-
NOARG (n=8), is important, as both reduced relaxin’s vasodilatory action. 
Manipulating the cGMP second messenger system with ODQ (n=8) greatly reduced 
relaxin’s action. but zaprinast (n=9) did not. Manipulation of EDHF with apamin 
and charybdotoxin (n=8) had no effect on relaxin’s action. Manipulation of 
prostanoids with indomethacin (n=10) reduced relaxin’s action but manipulation of 
cAMP with milrinone (n=8), had no effect. 
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iv)relaxin and small human pulmonary arteries: We determined, using wire 
myography, that relaxin is not a vasodilator of small pulmonary resistance arteries 
(n=5).  
v)relaxin and large calibre vessels: We determined, using the organ bath technique, 
that relaxin is not a vasodilator of larger calibre arteries i.e. internal mammary 
arteries removed from patients during coronary artery bypass surgery (n=5).Relaxin 
is not a venodilator studying saphenous veins removed from patients during 
coronary artery bypass surgery (n=5). 
vi)transmyocardial and transpulmonary gradient of relaxin: Plasma relaxin 
concentrations were measured using a validated assay. Samples were taken from 
patients undergoing CABG surgery, from the aorta, coronary sinus, pulmonary 
artery and pulmonary vein. We found that in 20 patients with normal left 
ventricular function that there was no transpulmonary gradient but there was a 
transcardiac gradient suggesting net cardiac extraction of relaxin.  
vii)prognostic value of relaxin in patients with chronic heart failure: Relaxin was 
compared with N-terminal pro brain natriuretic peptide to determine whether 
relaxin is of prognostic importance. Plasma concentrations of the hormones were 
measured in 87 patients admitted with CHF. These patients were followed up for a 
year during which time hospitalisations due to CHF and death were recorded. 
While NT-proBNP was found to be a powerful and independent predictor of 
outcome in these patients, relaxin was not. 
 
CONCLUSION. 
In addition to its established role in pregnancy, relaxin has many other actions. In 
particular, its antihypertensive, antithrombotic and vasodilatory properties suggest 
that relaxin may have a central role in cardiovascular regulation.  
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1.1 THE DISCOVERY OF RELAXIN. 
 
Relaxin, a peptide hormone, is a member of the insulin-like growth factor family 
with a molecular weight of 6000 daltons. It is made up of 53 amino acids with two 
disulfide-linked chains, A and B, with B bearing the receptor interaction site (Fig 
1). 
 
Structure of Relaxin 
 
(Adapted from Teichman et al, 2008). 
 
Discovered in 1926 by Frederick Hisaw, it is best known as a hormone of 
parturition, responsible for structural remodeling of the birth canal. This effect is 
thought to reflect complex actions on reducing fibroblast collagen synthesis and 
enhancing collagen breakdown (Bani, 1997). Hisaw first reported on the relaxation 
of the interpubic ligament of female guinea pigs following injections of serum 
from pregnant guinea pigs or rabbits (Hisaw, 1926). Four years later, Hisaw and 
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his group (Fevold et al, 1930) obtained a crude aqueous extract from sow corpora 
lutea with chemical characteristics of a peptide and which retained the property to 
elongate the interpubic ligament. This substance was identified as a new hormone 
and was given the name “relaxin”. 
 
1.2 RELAXIN FAMILY PEPTIDES 
 
The relaxin family peptides are a sub-group of the relaxin- insulin peptide family. 
All peptides within this family have a uniform two chain structure, with two inter-
chain and one intra-chain disulphide bond. In the human, there are seven relaxin 
family peptides: the human gene 1 (H1-relaxin), human gene 2 (H2-relaxin, 
commonly referred to as relaxin and equivalent to other species’ relaxin-1) and 
human gene 3 (H3-relaxin), and the insulin/relaxin-like peptides INSL3, INSL4, 
INSL5 and INSL6. Currently only four of the peptides have identified receptors, 
although there is a degree of cross-reactivity between peptides and receptors. 
 
  
1.3 RELAXIN RECEPTORS. 
 
It was with great excitement within the world of relaxinologists in 2002, the news 
was received that the relaxin receptors had now been identified. Hsu et al, 
described two G-protein coupled receptors LGR7 (Leucine-rich repeat containing 
guanine nucleotide binding receptor 7) and LGR8 that mediate the action of relaxin 
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through a cAMP dependent pathway (Hsu et al, 2002). They transfected cells with 
known G-protein coupled receptors with no known ligands. Treatment of these 
cells with porcine relaxin resulted in a dose dependent increase in cAMP 
production. LGR7 and LGR8 were not affected by treatment with insulin or insulin 
growth factor I or II (despite these proteins having a similar domain arrangement to 
prorelaxin, the precursor of relaxin). As relaxin belongs to the group of peptide 
hormones that includes insulin, the finding that relaxin receptors are G-protein 
coupled receptors rather than an orphan membrane-associated tyrosine kinase 
receptor resembling those that bind to insulin, is surprising.  
 
The expression pattern of these receptors was also examined. LGR7 was expressed 
in the brain, kidney, testis, placenta, uterus, ovary, adrenals, prostate, skin and 
heart whereas LGR8 was mainly present in brain, kidney, muscle, testis, thyroid, 
uterus, peripheral blood cells and bone marrow. The wide distribution of these 
relaxin receptors is in keeping with relaxin’s pleiotropic actions. 
 
Meanwhile, a group of investigators at the Howard Florey Institute in Australia, 
discovered relaxin-3. (Bathgate et al, 2002). An intriguing finding of relaxin-3 was 
its nearly exclusive expression in the brainstem. Subsequent searches of all 
available genomes using the relaxin-3 sequence found that relaxin is not 
mammalian specific. Relaxin-3 sequences were found in fish species (zebrafish, 
fugufish and Tetraodon, a frog (Xenopus) and a chicken. Hsu et al demonstrated 
that relaxin-3 was capable of activating LGR7 relaxin receptor but not LGR8.  
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The discovery that the orphan receptor LGR7 is the relaxin receptor was largely 
attributable to the pursuit of an idea raised by the combination of the similarity of 
the structure of LGR7 to LGR8 and the similarity of the structure of relaxin to 
INSL3 (gene encoding insulin-like peptide) (Hsu et al, 2002). LGR7 and LGR8, 
which are 757 (Hsu et al, 2002) and 737 (Overbeek et al, 2001) amino acids in 
length, respectively, share about 60% amino acid sequence identity and contain 10 
leucine-rich repeats in their large N-terminal extracellular domain. Two orphan G-
protein-coupled receptors designated GPCR135 and GPCR142 were recently 
proposed as putative receptors for relaxin-3 (Liu et al, 2003a,b). Both receptors 
belong to the type I family of GPCRs. Unlike LGR7 and LGR8, GPCR135 and 
GPCR142 have short N-terminal extracellular domains, and they contain only 469 
and 374 amino acid residues, respectively. 
 
With the discovery of more relaxin receptors, it was decided by the International 
Union of Pharmacology Committee on Receptor Nomenclature and Drug 
Classification (NC-IUPHAR), established in 1987, that the nomenclature for 
relaxin receptors should be examined (Table 1.1). Led by Professor Summers, 
Professor of Pharmacology, University of Monash, Australia, a review was 
published in 2006 with the revision of the nomenclature for the relaxin family 
peptides and their receptors (Bathgate et al, 2006).  
 
Relaxin receptors have now been identified in many tissues including reproductive 
tissues, cardiovascular and renal systems and the brain. Table 1.2 provides a 
 32 
summary of the distribution of human tissues where RXFP receptors 1 to 4 have 
been detected. 
 
 
 
Table 1.1.  Recommendations for the Nomenclature of Receptors for Relaxin 
Family Peptides 
 
 
 
 
 
 
 
 
 
RXFP = Relaxin Family Peptide Receptor 
LGR = Leucine-Rich Repeat Containing Guanine Nucleotide Binding Receptor 
GPCR = G-Protein-Coupled Receptor 
Adapted from Bathgate et al, 2006 
 
 
 
 
RECEPTOR PREVIOUS NAME 
RXFP 1 LGR7 
RXFP 2 LGR8 
RXFP 3  GPCR135 
RXFP 4 GPCR142 
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Table 1.2  Distribution of Receptors for Relaxin and Relaxin Related Peptides 
in Humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*mRNA by Northern blot analysis, **protein by immunohistochemical analysis 
Adapted from Bathgate et al, 2006. 
Tissue RXFP 1 RXFP 2 RXFP 3 RXFP 4 
Ovary mRNA* 
  
mRNA 
Uterus mRNA mRNA 
 
mRNA 
Placenta mRNA 
  
mRNA 
Breast protein** 
   
Testis mRNA mRNA mRNA mRNA 
Prostate mRNA 
  
mRNA 
Brain mRNA mRNA mRNA mRNA 
Pituitary  
 
mRNA 
 
Kidney mRNA mRNA 
 
mRNA 
Heart mRNA 
  
mRNA 
Lung mRNA 
   
Liver mRNA 
   
Muscle mRNA mRNA 
 
mRNA 
Thyroid mRNA mRNA 
 
mRNA 
Adrenal mRNA 
 
mRNA mRNA 
Skin mRNA 
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RXFP1 and RXFP2 are both classified as type C LGRs. Figure 1.2 below is a 
schematic diagram of a type C LGR. 
These receptors have a large and distinctive ectodomain encompassing an LDL 
class A (LDLa) module at the extreme N-terminus followed by 10 LRR (leucine 
rich repeats), a unique hinge region leading into the transmembrane domain (seven 
transmembrane helices) and an intracellular C-terminal tail. The LDLa module 
distinguishes RXFP1 and RXFP2 from other LGR receptors and other GPCRs. 
 
 
Figure 1.2 Relaxin Receptor. 
 
 
 
Adapted from van der Westhuizen et al, 2008 
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1.4 RELAXIN COMPARED WITH INSULIN. 
 
Relaxin was compared to insulin as early as 1930. Both porcine relaxin and insulin 
have a molecular weight of 6000 daltons and consist of two chains, a smaller A 
chain and a larger B chain. With the elucidation of the first primary structure of 
relaxin and the positive identification of the crosslink pattern, a direct comparison 
of the structures of these two hormones became possible. Surprisingly only a small 
number of amino acids are identical in insulin and relaxin. Six of the eight 
identities are the cysteines from an insulin-like disulfide structure (Schwabe and 
McDonald, 1977), and two additional homologous residues are the structurally 
important glycines of the B chains (B11, B23). 
 
Amino acid residues forming the hydrophobic core of insulin are hydrophobic in 
relaxin as well and the helical segments localized in the N-terminal and C-terminal 
region of the A chain and the mid-region of the B chain of relaxin contain amino 
acids that would also be consistent with helical conformations. The three glycine 
residues of the insulin B chain allow for β-turn-formation, and since the two 
glycines in the relaxin B chain are homologous, two of the three β-turns may be 
expected to occur in relaxin. 
 
Although there is strong evidence that relaxin is structurally related to insulin there 
are also distinct differences in terms of the surface properties of these two 
hormones, i.e. all relaxins of known primary structure are basic proteins whereas 
 36 
insulins are generally acidic proteins. In spite of overall structural similarities 
between insulin and relaxin the primary sequences vary sufficiently to eliminate all 
antigenic and biological cross-reactivity (Schwabe and Bullesbach, 1990). 
 
 
1.5 RELAXIN IN OTHER ANIMALS. 
 
Soon after its discovery in the ovaries of guinea pigs, investigators became curious 
to establish how widely distributed relaxin is in the animal kingdom. (Schwabe and 
Bullesbach, 1990). Using the guinea pig relaxation assay, it has been possible to 
find out that relaxin is not only a hormone of viviparity in mammals. There have 
been reports of relaxin in shark and whale ovaries as well as rooster and armadillo 
testes. Pregnant bats have also been found to rely on relaxin for propagation. 
Detection of relaxin in these unusual places has been confirmed at least in part by 
isolation and sequence analysis. In the dog, relaxin persists after pregnancy during 
lactation. Although the source of relaxin in the dog is not known, it has been 
suggested that both ovaries and the placenta might be a site of synthesis. 
Postpartum persistence of relaxin during lactation and the discovery of an immuno-
reactive relaxin-like component in the milk of Labrador retrievers suggest the 
mammary gland as an additional source. (Steinetz et al, 1987).  
 
Preliminary reports of relaxin in protozoa have been described by Schwabe et al 
(Schwabe et al, 1983) and immunoreactive molecules have also been detected in 
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prokaryotes (Bacillus subtilis) and even in lower plants (Spirogyra) by 
radioimmunoassay (RIA) with sheep anti-porcine relaxin antibodies. Whilst these 
studies are in need of confirmation, similar findings have been reported with 
insulin (LeRoith et al, 1980, 1981) which increases the likelihood that the genes 
for relaxin and insulin are present in unicellular life and in the plant kingdom. 
 
A plethora of relaxin functions has been proposed on the basis of physiological 
studies in a large variety of animals. The single most characteristic property of 
relaxin appears to be the widening of the birth canal in mammals prior to 
parturition. However, the response of different components of the birth canal, vary 
to differing degrees in various species. For example, the symphysis pubis relaxes 
proportionately less in women than in mice, guinea pigs or bats. In humans, other 
parts of the pelvic girdle, such as the sacroiliac joint are also affected whereas in 
guinea pigs major remodeling occurs only in the symphysis pubis. 
 
 
1.6 THE PRODUCTION OF RELAXIN IN HUMANS. 
 
Relaxin is produced in the corpus luteum, placenta, prostate (in men) and the heart. 
In humans, three molecular forms, each encoded by separate genes, have been 
identified - H1, H2 and H3. H1 and H2 are found on chromosome 9 while H3 is 
found on chromosome 19. Only the H2 form circulates in plasma. In women, H2 is 
also expressed in the corpus luteum, endometrium, placenta and breast, while H1 is 
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expressed only in the placenta.  In men, both H1 and H2 are expressed in the 
prostate gland. H3, which has only recently been identified, (Bathgate et al, 2002) 
is expressed in the brainstem.  Relaxin mRNA   H1 and H2 are expressed in human 
left ventricle, right atrium, the internal mammary artery and saphenous vein. 
 
 
1.6.1 In Health.  
 
Relaxin is produced in both pre- and post-menopausal women and also in men.  
The highest plasma concentrations are attained during pregnancy at around 1-
2ng/ml, when relaxin is produced mainly by the corpus luteum and also the 
placenta. Relaxin can be found in peripheral blood in conception cycles by the time 
of missed menses and concentrations rapidly rise and peak by the middle of the 
first trimester of pregnancy. Serum levels then fall by approximately 20% and 
remain stable throughout pregnancy. (Weiss, 1991).  
 
As previously stated, relaxin prepares the birth canal for delivery. Initially 
however, relaxin increases the secretion of prostacyclins which decrease 
myometrial contractility. Later, relaxin ripens the human cervix at term therefore 
inducing labour and plays a part in the changes in pelvic diameter as demonstrated 
radiographically.with pubic symphysis changes. Elevated first trimester relaxin 
levels have been shown to be associated with an increased risk of premature 
delivery (Weiss et al, 1993).  
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Another action of relaxin during pregnancy is on glucose metabolism. Relaxin 
increases the affinity of insulin to its own receptor in isolated human adipocytes in 
vitro from women at term gestation. Thus it is possible that circulating relaxin may 
have a protective effect from the diabetogenetic effects of pregnancy (Weiss, 
1991). 
 
In non-pregnant women, relaxin is produced by the corpus luteum.  Levels during 
the menstrual cycle are highest after the luteinising hormone (LH) surge, around 
30-150 pg/ml. Since this is the period of nidation, a role for relaxin during this 
phase has been postulated.  
In men, relaxin is produced by the prostate gland. This is verified by taking semen 
samples that exclude testicular and seminal vesicle components, such as samples 
from men who have had a vasectomy or from men with congenital absence of the 
vas and seminal vesicles, where relaxin concentrations are undiminished. (Weiss, 
1991). This observation has been confirmed by the finding that in split ejaculates 
the first part of the ejaculate is richer in relaxin. The first part of the split ejaculate 
is predominantly prostatic, whereas, the second part is predominantly from the 
seminal vesicles. (DeCooman  et al, 1983).  
 
It has been demonstrated that physiological concentrations of relaxin are effective 
in increasing sperm penetration into cervical mucus, which is the first barrier that 
sperm meets in traversing the female genital tract (Brenner et al, 1984). Relaxin 
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also significantly increases the motility of sperm in situations of decreased motility 
i.e. when sperm motility is apparently optimal, as in normal samples, addition of 
relaxin does not produce a further increase in motility. (Lessing et al, 1986). 
Relaxin secretion into seminal plasma by the male represents a novel physiological 
mechanism for hormone delivery. 
 
 
1.6.2 In Disease.  
 
Plasma relaxin concentrations are also increased in the pathophysiological states.  
The heart has been identified both as an additional source of relaxin and also as a 
target for this hormone.  Specific binding sites for relaxin have been found in 
cardiac tissues, particularly the atria (Taylor et al, 1994), (Osheroff et al, 1992). 
Relaxin has been reported to increase natriuretic peptide secretion and to have 
positive chronotropic actions. (Toth et al, 1996) Of note, cardiac secretion and 
plasma concentrations of relaxin increase in heart failure and these increases are 
greatest in those patients with the most severe degrees of failure (15-20pg/ml) 
(Dschietzig et al, 2001). This suggests that the heart may be producing relaxin as a 
“compensatory” or protective response, consistent with its role as an endocrine 
organ. This will be discussed in more detail later. 
 
Hocher et al, investigated the impact of relaxin on deaths in patients with end-stage 
kidney disease (ESKD). Patients with ESKD have a reduced life expectancy 
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mainly as a result of cardiovascular disease. 245 patients (123 male) on long term 
haemodialysis were followed up for 1140 days. Survival was compared by the 
Kaplan-Meier method and Cox regression analysis. Elevated serum relaxin 
concentrations (greater than median of 28.8 pg/ml) independently predicted all-
cause and cardiovascular death in male but not female patients (Hocher et al, 
2004).  
 
1.7 SECRETION OF RELAXIN. 
 
It is known that relaxin is produced in the corpus luteum. Taylor and Clark 
examined whether prostacyclin may act as a secretagogue for relaxin release from 
cultured porcine luteal cells (Taylor and Clark, 1987). 
The release of relaxin from cultured porcine luteal cells (derived from pregnant 
sows) was detected by a reverse haemolytic plaque assay. In this assay, luteal cells 
are cocultured in monolayers with protein-A coupled ovine erythrocytes. In the 
presence of porcine relaxin antiserum and complement, a zone of haemolysis i.e. a 
plaque, develops around relaxin-releasing luteal cells. Treatment with a 
prostacyclin analogue, carba-prostacyclin, significantly accelerated the rate of 
plaque formation in a dose dependent manner. This analogue, chemically stable in 
aqueous medium, exerts potent PGI-2-like effects both in vivo and in vitro. 
Therefore, it appears that PGI-2 acts as a secretagogue for relaxin release from 
cultured porcine luteal cells.  
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Taylor and Clark also studied what may act as a local inhibitory mechanism to 
regulate relaxin secretion (Taylor and Clark, 1992). They examined basic 
fibroblast growth factor (FGF) which is involved in the development and function 
of the corpus luteum and has been shown to regulate ovarian steroidogenesis 
(Baird and Hsueh, 1986). Exposure of luteal cell-containing monolayers to basic 
FGF resulted in a significant reduction (p<0.05) in the rate of relaxin-induced 
plaque formation. In addition, PGE-2-stimulated secretion of relaxin by porcine 
luteal cells was diminished by basic FGF suggesting that there stimulatory and 
inhibitory agents acting to achieve fine control of relaxin secretion. 
 
1.8 VASCULAR ACTIONS OF RELAXIN. 
 
Before discussing the current literature on the vascular actions of relaxin, I will 
briefly describe the anatomy and physiology of blood vessels. 
 
1.8.1 Anatomy and Function of Blood Vessels  
 
Arteries have three layers: the intima, media and adventitia. The intima consists of 
the vascular endothelium, which is a single layer of cells and a thin layer of 
connective tissue. It is separated from the media by the internal elastic lamina 
made of elastin and fibrous tissue. The media consists of fibrous tissue, vascular 
smooth muscle and elastin. The media is separated from the adventitia by the 
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external elastic lamina. The adventitia consists of collagen and fibrous tissue that 
forms loose connective tissue. 
 
The connective tissue of large arteries contains more elastin, whereas smaller 
arteries have more collagen. The elastic properties of healthy large arteries, such as 
the ascending aorta, help to cushion the stroke volume, decrease the work of 
ejection by the left ventricle and maintain pressure during diastole. The smaller 
arterioles and resistance arteries (the focus of my research) are able to regulate 
peripheral resistance by changing vascular smooth muscle tone to alter the lumen 
size. 
 
 
1.8.1.1 Endothelial function 
 
The healthy endothelium is an autocrine and paracrine organ that produces 
substances that decrease vascular smooth muscle tone and inhibit inflammation 
and thrombosis. These substances include nitric oxide, prostacyclin other 
endothelium dependent vasodilators such as endothelium-derived hyperpolarizing 
factor and plasminogen activators. In disease states or after injury by factors such 
as abnormal strain, temperature or risk factors for atherosclerosis, the endothelium 
produces substances that increase vascular tone, promote inflammation and 
enhance thrombosis. These substances include cytokines, growth factors, 
endothelins and plasminogen inhibitors. 
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The principle vasodilators produced by the endothelium include nitric oxide, 
prostacyclin and endothelium- derived hyperpolarising factor (EDHF). Of these 
nitric oxide has a central role in mediating many functions of the endothelium 
aside from vasodilation (Alexander and Dzau, 2000), (Kinlay, 2007). 
 
 
1.8.1.2 Nitric oxide  
 
Nitric oxide is generated in the endothelium from the amino acid L-arginine by 
nitric oxide synthase (NOS). Nitric oxide diffuses through the arterial wall and 
enters vascular smooth muscle cells in the media, where it increases the activity of 
guanylate cyclase and the concentration of cyclic guanosine monophosphate 
(cGMP). The increased level of cGMP relaxes vascular smooth muscle and leads 
to vasodilation. 
 
1.8.1.3 Prostacyclin 
 
Prostacyclin is another endothelial product that induces arterial dilation. It is 
produced from arachidonic acid by cyclooxygenase in response to shear stress or 
certain factors that also increase nitric oxide production. Prostacyclin activates 
adenylate cyclase to increase production of cyclic adenosine monophosphate 
(cAMP). 
 45 
  
1.8.1.4 EDHF 
 
A residual vasodilatory response to various stimuli after blocking nitric oxide and 
prostacyclin generation led to the discovery of EDHF. EDHF appears to be more 
important in the small arteries than large conduit arteries. 
 
1.8.2 Systemic Arteries. 
 
Relaxin may be a circulating endogenous agent capable of regulating vascular tone 
(Bani et al, 1998). In keeping with this hypothesis, relaxin has vascular effects.  
Though the focus of existing studies has been on the uteroplacental bed, which is 
not typical of the systemic or pulmonary circulations, two recent studies have 
examined the effect of this hormone in other vessels.  Bani et al examined vascular 
smooth muscle cells cultured form bovine aorta. These cells were incubated with 
relaxin at concentrations ranging from 1nmol/L to 1µmol/L. The expression and 
activity of nitric oxide synthase, production of nitric oxide and the intracellular 
levels of cGMP and calcium (Ca2+) were determined. The cell morphology and 
signal transduction mechanisms of these bovine aortic smooth muscle cells in 
response to relaxin were also studied. Relaxin was found to increase the expression 
and activity of inducible nitric oxide synthase (iNOS), nitric oxide production and 
intracellular concentrations of cyclic GMP. Concurrently, relaxin significantly 
decreased cytosolic Ca2+ concentrations and caused changes in cell shape and the 
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actin cytoskeleton that were consistent with cell relaxation (Bani et al, 1998). 
Danielson et al have shown that relaxin causes renal vasodilation and this will be 
discussed further in a later section (Danielson et al, 1999). 
 
Relaxin has recently been described as a "potential new treatment for 
vasoconstrictive disorders". (Whelan J, 2000).  However, its vasodilatory action 
was first recognised over forty years ago. Casten et al in an uncontrolled trial, 
found that, in patients with severe obliterative peripheral vascular disease (PVD), 
treated with intramuscular injections of porcine relaxin, there was consistent 
healing of ischaemic ulcerations (Casten et al, 1960). Patients also reported an 
improvement in symptoms of intermittent claudication and rest pain although there 
was a return of symptoms with cessation of the treatment. Interestingly, patients in 
this trial who also had coexistent severe coronary artery disease, reported a 
dramatic improvement with regard to their nitroglycerin requirements. One patient 
who, prior to treatment, had required an average of 100 nitroglycerin tablets per 
week, only needed 2-3 tablets during relaxin therapy.  
 
A phase II clinical trial of patients with peripheral arterial disease who have 
recently undergone surgical revascularization of a lower extremity and who have at 
least one unhealed ischaemic or operative wound in that region, is currently 
underway. Treatment consists of a subcutaneous infusion of relaxin at 10, 25, or 
100µg kg -1 day-1 or placebo. The study will evaluate the time to complete wound 
healing as well as a range of related parameters. As peripheral arterial disease is 
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often accompanied by renal disease, the study will also evaluate the effect of 
relaxin on renal function (Whelan, 2000). The results of this study have yet to be 
published. 
 
It has been noted that Raynaud's phenomenon, related to vasoconstriction in the 
arteries in the fingers, disappears during pregnancy (when relaxin levels are at their 
highest). (Casten, 1958). This observation would therefore support relaxin’s 
vasodilatory effect in humans.  
Also in keeping with its vasodilatory action, relaxin has been found to decrease 
blood pressure and blunt responses to vasoconstrictors of mesenteric vessels in 
spontaneously hypertensive rats. Massicotte et al investigated the vascular 
reactivity to angiotensin II, arginine-vasopressin and norepinephrine in the 
perfused mesenteric artery and portal vein of control and relaxin-treated virgin 
spontaneously hypertensive rats. The latter received an intravenous infusion of 
75ng/hr purified rat relaxin for 2 days, whereas the controls were given an equal 
infusion of saline. All of the animals were then killed and their tissues processed 
for in vitro study. In the perfused mesenteric artery, the concentration-response 
curves for arginine-vasopressin and norepinephrine were shifted to the right by a 
factor of about 2 (p<0.05 and p<0.005, respectively) after relaxin treatment. In the 
isolated portal vein, the response to angiotensin II was not affected; the effect of 
norepinephrine was slightly displaced to the right (increase in EC50) and the 
maximum response remained unchanged. Relaxin, however, has no effect on 
Wiskar - Kyoto controls. (Massicotte et al, 1989).  
 48 
1.8.3 Renal Arteries. 
 
Relaxin is a potent renal vasodilator. (Danielson et al, 1999).  After several days of 
treatment with either purified porcine relaxin or recombinant human relaxin, 
effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) increased 
by 40% in adult female rats. This was also observed in ovariectomized rats, 
suggesting that neither oestrogen nor progesterone is necessary for the renal 
response to relaxin. Further to this, the role of relaxin on the renal vasculature 
during pregnancy has been investigated. Striking changes are seen in the maternal 
cardiovascular system during pregnancy. Cardiac output, global arterial 
compliance, effective renal plasma flow (ERPF) and GFR rise from 30% to 80%. 
Vascular resistance and blood pressure decrease. These alterations begin 
immediately after conception, peak by the end of the first or the beginning of the 
second trimester and persist throughout gestation. Traditionally, oestrogen has 
been viewed as the uterine and systemic vasodilator of pregnancy but this hormone 
has little effect on the renal circulation. (Christy et al, 1974).  
 
Novak et al used two approaches to eliminate relaxin or its biological activity from 
the circulation: ovariectomy and administration of relaxin neutralizing antibodies. 
(To maintain pregnancy in the ovariectomized rats, silastic tubes containing 17β 
oestradiol and progesterone were implanted). Neutralizing mAb against rat relaxin 
(MCA1) or control mAb against fluorescein (MCAF) was administered daily. They 
showed that the relaxin neutralizing antibody administered to pregnant Long-Evans 
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rats completely abolished the increase in GFR and ERPF associated with 
pregnancy.  The same was seen in the ovariectomized, steroid replaced rats. 
Therefore, relaxin is in fact essential for renal vasodilation during pregnancy. 
(Novak et al, 2001).                 
Evidence of interaction between relaxin and other vasoactive peptides has been 
demonstrated in the renal arteries. Relaxin attenuates the vasoconstrictor effect of 
angiotensin II (Danielson et al, 1999). 
 
 
1.8.4   Relaxin and Myogenic Reactivity. 
 
Myogenic reactivity is defined as the response (either constriction or dilation) of an 
artery to a rapid change in intraluminal pressure. Novak et al investigated the 
myogenic responses of small renal and mesenteric arteries in relaxin-treated Long-
Evans rats. They found that arteries from relaxin-treated rats constrict less than 
those from vehicle-treated rats in response to an increase in intraluminal pressure. 
(Novak et al, 2002). 
 
In a previous study, Novak et al had demonstrated that circulating relaxin mediates 
myogenic reactivity of isolated small renal arteries in gravid rats. When relaxin 
neutralizing antibodies were administered or pregnant rats were ovariectomized, 
myogenic reactivity was restored to virgin levels (Novak et al, 2001). Thus Novak 
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et al, have demonstrated the influence of relaxin on myogenic reactivity in both the 
pregnant and non- pregnant state. 
 
 
1.8.5 Penile Arteries .  
 
Further evidence of relaxin’s vasodilatory action has been demonstrated. Bigazzi et 
al showed that local injection of relaxin into the cavernous body of human 
volunteers increased blood flow in the deep penile artery. This was evaluated by 
echo Doppler apparatus (Bigazzi et al, 1995).  
 
 
1.8.6 Uteroplacental Arteries.  
 
It should be noted though that relaxin does not have a vasodilatory effect on all 
blood vessels. Peterssen et al, investigated the effect of synthetic human relaxin 
(hRLX-2) on isolated human myometrium and on uteroplacental arteries from term 
pregnant women. Relaxin did not dilate the arteries preconstricted with 
norepinephrine, endothelin or U46619. (Petersen et al, 1991). 
 
This is in contrast with the findings of Longo et al who investigated the effects of 
recombinant human relaxin on rat uterine arteries and myometrial rings. In rats, 
relaxin did cause uterine artery relaxation. This was noted to be greater at mid 
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pregnancy compared to term. Relaxin was also found to inhibit spontaneous 
contractions at mid pregnancy but not at term. Relaxin had no effect on oxytocin- 
or indolactam-V-induced contractions. (Indolactam-V is a protein kinase C 
activator). (Longo et al, 2003). 
 
1.8.7 Pulmonary Arteries.  
 
During my MD thesis, I have investigated the potential role of relaxin in human 
pulmonary resistance arteries.  Prior to this, the vasoactive role of relaxin in human 
pulmonary arteries had not been described. The methods and results shall be 
discussed in detail in later chapters (2 and 3).  
 
 
1.8.8 Veins. 
 
Prior to my work on human long saphenous veins as part of my MD thesis, the 
effect of relaxin on the human venous system had not been described. The 
methodology used will be described in Chapter 2 and the results will be described 
in Chapter 5. 
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1.9  RELAXIN AND THE HEART. 
 
In recent years, evidence is accumulating that relaxin has a major influence on the 
cardiovascular system and may be involved in cardiovascular regulation. (Bigazzi 
et al, 2001). Relaxin has positive chronotropic actions and this may contribute to 
the increase in cardiac output seen in early pregnancy. During the first trimester, 
cardiac output increases by about 40%. During this time relaxin levels are at their 
highest peaking at week 10.   
 
1.9.1 The Heart as a Source of Relaxin 
 
The heart has been identified both as an additional source of relaxin and also as a 
target for this hormone (Taylor et al, 1994).  Antibody-directed, complement-
induced erythrocyte lysis (reverse haemolytic plaque assay) around atrial 
cardiocytes was used to determine whether this cell type possesses the capacity to 
secrete relaxin. After two hours of incubaton, 33 +/- 4% (n=3) of cardiocytes 
derived from the atria of neonatal rats secreted detectable amounts of 
immunoreactive relaxin (i.e. formed plaques) when cultured in monolayers. The 
observation that only one third of atrial cardiocytes secreted relaxin under basal 
conditions is consistent with a similar study which reported that only a subset of 
(27%) of rat atrial cardiocytes secreted atrial natriuretic peptide (ANP) under non-
stimulated conditions.  (Miller and Southerland, 1990). 
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Increased culture time of cardiocytes failed to increase the fraction of cardiocytes 
that secreted relaxin. However, the cumulative amount of relaxin secreted after 3 
hours of incubation (plaque area) was 31% greater (p<0.05) than the amount of 
hormone present after 1 hour of incubation, providing evidence for sustained 
peptide secretion by cultured cardiocytes. The authors conclude that these data 
suggest that the source of the endogenous ligand for the specific and high-affinity 
relaxin receptors located in the rat atria is the atrial cardiocyte itself, following on 
from the work performed by Osheroff et al  (Osheroff et al, 1992). 
 
1.9.2 Relaxin and Atrial Binding Sites. 
 
Osheroff et al, demonstrated that specific binding sites for relaxin can be found in 
cardiac tissues, particularly the atria. Nine different rat tissues, including the liver, 
spleen, thymus, kidney, adrenal gland, heart, lung, skin and testis were examined 
for the binding of the tracer 32 P- relaxin (phosphorylated relaxin). Of all of these 
tissues, specific binding was seen clearly in the heart atria. The ventricles by 
contrast did not show detectable binding under these experimental conditions. The 
specificity of binding was demonstrated by the binding displacement of 100pM 32 
P- relaxin by 100nM unlabelled relaxin but not by 100nM insulin like growth 
factor I (IGF-I), insulin, angiotensin II and atrial natriuretic peptide (Osheroff et al, 
1992). 
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These specific and high affinity relaxin receptors present in both male and female 
rat atria are regulated differently than the relaxin receptors in the uterus. It was 
found that the relaxin binding in the uterus was diminished by 53% overall 
following ovariectomy but was restored to 90% of normal levels when treated with 
oestrogen. Relaxin binding in the heart however was not affected by ovariectomy 
or oestrogen therapy.    This is in keeping with the findings, previously described, 
demonstrating the lack of oestrogen requirement of relaxin for its renal 
vasodilatory action. (Danielson et al, 1999). 
 
 
1.9.3 Inotropic and Chronotropic Effects of Relaxin. 
 
The cardiac effects of human gene-2 relaxin (hRlx-2), in isolated rat atria, has been 
investigated (Kakouris et al, 1992). Using hearts from male Sprague-Dawley rats, 
atria were removed and mounted separately under a resting tension of 0.25g in 
20ml organ baths containing Krebs’ bicarbonate buffer. Right atria were allowed to 
beat spontaneously, whereas left atria were driven at 5 Hz with square-wave pulses 
of 2ms at 1.5 times the threshold voltage with a stimulator. Synthetic hRlx-2 (0.03-
3 nmol/l) increased the heart rate of contraction in rat spontaneously beating right 
atria by a maximum of 131 (15) beats per minute from a baseline of 179 (25) beats 
per minute. The EC50, i.e. the concentration required to produce 50% of the 
maximal response, was 0.09 (SE 0.03) nmol/l. In the electrically driven left atria, 
synthetic hRlx-2 increased the force of contraction by a maximum of 0.19 (0.03) g 
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from a baseline of 0.15 (0.02) g (EC50 =0.31 (0.02) nmol/l).  The authors noted that 
the EC50 value of 0.1-0.3 nmol/l for synthetic hRlx-2 in isolated rat atria is lower 
than that of endothelin, angiotension II or isoprenaline, making relaxin one of the 
most potent chronotropic and inotropic agents known.  
 
More recently, Debrah et al, have shown that relaxin increases the cardiac output 
and reduces systemic arterial load in hypertensive rats (Debrah et al, 2005). Two 
models were used in this study: Long-Evans rats chronically administered with 
angiotensin II (AII) and spontaneously hypertensive rats (SHR). Debrah et al had 
noted and as I describe elsewhere, relaxin antagonizes the action of AII in rats. 
(Danielson et al,1999). Cardiac output and systemic arterial load were quantified 
by systemic vascular resistance (SVR) and AC g   (global arterial compliance). Rats 
were either administered relaxin acutely over a 6 hour period or chronically over 6 
days. 
 
In rats with AII-induced hypertension, acute RLX administration (up to 6 hours) 
significantly increased CO and AC g    (24.9+/-3.9 and 34.3+/-12.6% above baseline 
respectively) and significantly decreased SVR (17.2+/-3.5%) without changing 
mean arterial pressure (MAP). In contrast, acute RLX administration to SHR and 
normotensive rats for up to 6 hours failed to produce any significant change in CO, 
AC g , SVR or MAP. However, chronic administration of RLX (1 to 7 days) to 
SHR yielded significant changes (24.0+/-8.1 and 22.3+/-6.6% increases in CO and 
AC g , respectively, and a 13.3+/-5.3% decrease in SVR with no change in MAP. 
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Therefore, the time course to RLX treatment is dependent on the model of 
hypertension as rats with AII-induced hypertension responded more rapidly to 
RLX administration than SHR.  
 
Debrah et al have since shown that relaxin is essential for the systemic vasodilation 
and increased global arterial compliance during early pregnancy in conscious rats 
(Debrah et al, 2006). They administered relaxin neutralizing antibodies daily 
beginning on day 8 of gestation to block the functional effects of circulating 
relaxin and used an antibody against fluorescein as a control. In the pregnant rats 
administered the relaxin neutralising antibody, there was no gestational increase in 
stroke volume, cardiac output and global arterial compliance or decrease in SVR, 
that would be expected and which was observed in the pregnant control rats. This 
suggests that relaxin mediates the transition of changes observed in the systemic 
circulation from the non-pregnant to the pregnant state in the rat model. 
 
1.9.4 Relaxin and Heart Failure. 
 
Relaxin production is increased in heart failure, higher levels correlating with the 
severity of heart failure. (Dschietzig et al, 2001). In this study, patients were 
classified as having severe heart failure if in functional class New York Heart 
Association (NYHA) class IV who required intensive care treatment for acute left 
heart decompensation (orthopnoea and signs of severe pulmonary congestion) with 
a pulmonary wedge pressure (PCWP) of >25mmHg and cardiac index (CI) < 2.5 
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l/min/m2 . Acute ischaemia was excluded on the basis of electrocardiography as 
well as kinetics of enzymes (troponins, creatinine kinase) and myoglobin. The 
mean left ventricular ejection fraction (LVEF) was 19%. Patients were assigned to 
the moderate congestive heart failure (CHF) group if in NYHA class  II and 
displayed a PCWP <20mmHg and a CI > 2.5 l/min/m2  . The mean LVEF of these 
patients was 27%. The controls were patients who underwent cardiac 
catheterization for suspected coronary artery disease and in whom no structural 
cardiovascular disease was detected. 
 
In all groups, catheters were positioned in the pulmonary artery (PA) (Swan Ganz), 
the coronary sinus (CS), and the left ventricle (LV) under fluoroscopic control. 
Blood sampling and haemodynamic measurements were then carried out. Whilst 
men and women with normal coronary arteries and normal left ventricular systolic 
function were noted to have plasma concentrations in the range 1-2 pg/ml, patients 
with mild to moderate heart failure, had plasma relaxin concentrations 5-10 pg/ml 
and those with severe heart failure concentrations of 15-20 pg/ml. Eleven out of 
the fourteen patients with severe CHF (i.e. 79%) showed higher relaxin plasma 
levels in the coronary sinus than in the left ventricle which indicates net coronary 
release of relaxin in the majority of patients suffering from severe heart failure. 
 
The same group found that myocardial expression of the two relaxin genes, (H1 
and H2) correlates with the severity of heart failure. For the RNA analysis, control 
samples were human total ventricular RNA from healthy individuals and a sample 
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from one donor heart that was not transplanted. Failing myocardium was from 
patients with dilated cardiomyopathy and ischaemic heart disease who underwent 
partial ventriculectomy or transplantation. 
 
Dschietzig et al demonstrated pronounced up-regulation of GAPDH-normalized 
H1 mRNA (failing hearts, 14.4+/-2.4 vs. non-failing hearts 1.0+/-0.5 arbitary units; 
<0.05) and a moderate increase in H2 mRNA (2.6+/-0.4 vs. 1.0+/-0.2 units, <0.05) 
in left ventricular specimens of failing hearts compared with non-failing hearts. 
Results for right atrial H2 mRNA also showed a more pronounced elevation in 
failing hearts (3.8+/-1.0 vs. 1.0+/-0.1 units, <0.05). In contrast, expression of 
relaxin mRNA did not appear to differ in mammary arteries and saphenous veins 
from patients with normal heart function and patients with chronic heart failure. 
Increased ventricular filling pressures results in up-regulation of relaxin 
expression. Elevation of left ventricular end diastolic pressure from 5 to 25mmHg 
up-regulates preprorelaxin (which processes the precursor of relaxin) mRNA in 
isolated rat hearts. In contrast, elevation of both right and left atrial pressures has 
no effect on the expression of relaxin mRNA. 
 
In severe heart failure, a significant inverse correlation was found between relaxin 
and endothelin-1 (ET-1).  ET-1 represents one of the most powerful mediators in 
CHF progression. Patients in this group (i.e. severe heart failure) with high relaxin 
levels had the lowest circulating levels of ET-1. It would seem, therefore, that 
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relaxin may be produced as a compensatory mediator in cardiovascular disease. In 
patients with moderate CHF and in controls, no such correlation was seen. 
 
1.9.5 NT pro BNP and Heart Failure 
 
Another peptide, N-terminal pro B type natriuretic peptide (NT pro BNP) has been 
shown to be elevated in patients with heart failure. As part of my MD thesis, I 
investigated whether the plasma concentration of relaxin predicts clinical outcome 
in patients with CHF and compared with this NT pro BNP (see chapter 6). I will 
therefore at this stage, describe the peptide NT pro BNP in more detail. 
In the early 1980s, DeBold et al observed that extracts of atrial tissue infused into 
rats caused a massive diuresis (DeBold et al, 1981). From this work came the 
isolation of atrial natriuretic peptide (ANP), the first in the family of natriuretic 
peptides (DeBold, 1985).  A decade later, the second member of the family was 
described, B-type natriuretic peptide (BNP).  Since then, four different natriuretic 
peptides have been described: ANP, BNP, C-type natriuretic peptide (CNP) and D-
type natriuretic peptide (DNP).  They all contain a characteristic 17 amino-acid 
ring structure, formed by a disulfide bridge between two cysteine residues.  The 
amino- and carboxy- terminal tail varies between the different peptides: ANP has a 
28 amino acid polypeptide, BNP a 32 amino acid polypeptide, CNP a 53 amino 
acid polypeptide and DNP a 38 amino acid polypeptide.  They all exist as pro-
hormones with relatively high molecular weight, which are cleaved to active 
moieties before release into the circulation.  
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BNP is released in bursts as a 108 amino acid prohormone which is then cleaved to 
form biologically active BNP, a 32 amino acid molecule and the 76 amino acid 
molecule, NT-proBNP.  Figure 1.2 summaries this process.   
 
Figure 1.3  Structure and formation of BNP and NT-proBNP (adapted from 
Hall, 2004). 
 
 
 
 
BNP, and more recently NT-proBNP have been recognised to be of particular 
importance in heart failure. The predominant source of BNP in humans is the 
ventricular myocardium (Hunt, 1997).  In patients with LV systolic dysfunction 
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both BNP and NT-proBNP are elevated, however, increases in NT-proBNP are 
two-to ten-fold greater than increases in BNP.  The explanation for this is unknown.  
Both BNP and NT-proBNP can be measured by radioimmunoassay (RI). The 
combination of its longer half-life and greater increases in heart failure, may make 
NT-proBNP a better marker of heart failure (Hunt, 1997).  Recently, NT-proBNP 
has been shown to be elevated in patients with heart failure, post-MI LV systolic 
dysfunction and asymptomatic LV dysfunction (Hobbs et al, 2002), (Masson et al, 
2002), (Hunt et al, 1997), (Richards et al, 1998) , (Groenning et al, 2002). 
 
 
1.9.6 Relaxin and Cardiac Anaphylaxis 
 
Cardiac anaphylaxis refers to the functional and metabolic changes in the heart 
caused by the anaphylactic release of histamine and vasoactive products of 
arachidonic acid cascade by mast cells and basophils. As in most type 1 
hypersensitivity-based diseases, histamine plays a key role in the pathophysiology 
of cardiac anaphylaxis. In the heart, mast cell activation and histamine release are 
controlled by multiple endogenous mechanisms, including adrenergic neural 
control, histamine-dependent negative feedback operated through H2 receptors and 
the endogenous generation of nitric oxide and carbon monoxide. 
 
A reliable model of cardiac anaphylaxis ex vivo can be reproduced using perfused 
hearts isolated from sensitized guinea pigs and subjected to challenge with the 
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specific antigen. A typical anaphylactic crisis is characterized by arrhythmias, 
sinus tachycardia and increase in the strength of contraction. These mechanical 
abnormalities are accompanied by a fast, short lasting decrease in the coronary 
flow followed by a sustained flow increase. 
 
Masini et al demonstrated that ex vivo perfusion of hearts isolated from ovalbumin-
sensitised guinea pigs with relaxin affords a marked protection against 
anaphylactic reaction induced by challenge with the specific antigen. They found 
that the protective effect of relaxin was exerted at low, nanomolar concentrations 
(30ngml -1) and for short exposure times (30 minutes). A significant reduction of 
histamine release from resident mast cells (the main repository of cardiac 
histamine) was seen. No significant changes were observed in beat rate or 
contraction strength. No short-lasting decrease in coronary flow took place and the 
subsequent flow increase was significantly higher than in the untreated control 
hearts (Masini et al, 2002). 
 
1.9.7 Relaxin and Prevention of Cardiac Ischaemia/Reperfusion Injury 
 
Relaxin has been shown, as detailed above, to increase coronary blood flow and 
acts as a positive chronotropic and inotropic agent in the heart. Perna et al, tested 
the therapeutic potential of relaxin in a swine model of ischaemia/reperfusion-
induced acute myocardial infarction which is used to test cardiotropic drugs.  
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Ischaemia for 30 minutes was obtained by transient ligation of the left anterior 
descending artery after the 2nd diagonal branch and was followed by reperfusion 
for a further 3 hours. Five minutes before reperfusion, lidocaine was administered 
to reduce the occurrence of lethal ventricular fibrillation. Relaxin was infused at 
reperfusion through the right atrial catheter. Measurements of blood and tissue 
markers of myocardial injury and inflammation were taken. In addition, functional 
evaluation of myocardial salvage by cardiac single- photon emission computed 
tomography (SPECT) was performed. By using the tracer, 201Thallium chloride 
(which is a potassium competitor and therefore labels viable cardiac cells), the 
investigators were able to distinguish between normal myocardium, ischaemic 
myocardium and irreversibly damaged myocardium. 
 
Administration of relaxin caused a statistically significant reduction of serum 
myoglobin, CK-MB and troponin T (markers of myocardial cell damage) which 
rose markedly in the control animals given the vehicle alone. Relaxin also reduced 
myeloperoxidase (MPO), a marker of inflammatory leukocyte infiltration and 
malondialdehyde (MDA), a marker of free radical-mediated cell damage. By 
SPECT analysis, in the relaxin treated swine, there was a striking reduction of the 
irreversibly injured myocardial tissue (Student’s t-test: p<0.05). The relaxin-
induced salvage improved contractile performance of the heart, indicated by a 
stable increase in cardiac index. The authors point out that the protection afforded 
by relaxin is exerted at plasma levels which are within the physiological range in 
humans. They feel that clinical trials with relaxin as adjunctive therapy to catheter-
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based coronary angioplasty in patients with acute myocardial infarction may be 
warranted (Perna et al, 2005). 
 
 
1.10 RELAXIN AND FLUID BALANCE. 
 
During pregnancy, there is a decrease in plasma osmolality which begins early 
around gestational week 5 in women which returns to normal by 2 weeks post 
partum. This has also been demonstrated in the rat where the decrease in plasma 
osmolality is thought to be due to a decrease  in both the threshold for thirst and for 
arginine vasopressin (AVP) release such that the relationship P osmol  /PAVP shifts to 
the left. Thus a decrease of about 10 mosmol/kg occurs because more water is 
drunk and less excreted because the PAVP  is seemingly inappropriately high for the  
P osmol . The decrease in P osmol   is dependent on the presence of the ovary and 
treatment of rats with various amounts of oestrogen and/or progesterone does have 
a small effect on the P osmol  /PAVP   relationship. However, treatment of rats or non-
pregnant women with the appropriate amount of ovarian steroids does not produce 
the changes in the P osmol  /PAVP   relationship seen in pregnancy. (Barron et al, 1986; 
Lindheimer et al, 1989). Weisinger et al, noted that relaxin concentration increases 
in the rat and in the pregnant women at the appropriate stage of pregnancy and 
investigated this further. They found that in ovariectomized rats treated with 
intravenous synthetic human relaxin, P osmol  was significantly lower (p<0.001) than 
that in the two control groups (either no treatment or treatment with vehicle), but 
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the PAVP  was unchanged. This decrease in osmotic threshold for AVP release 
produced by intravenous relaxin in ovariectomized rats, which is observed in 
pregnant women and rats, was achieved at concentrations of relaxin found in 
pregnant rats. Weisinger et al were unable to demonstrate the exact mechanism of 
action.  
 
Robertson et al, showed that relaxin stimulates vasopressin secretion from the 
posterior pituitary gland, triggering thirst and increasing water intake. (Robertson 
et al, 1991).   
This key role in fluid balance played by relaxin during pregnancy has been further 
demonstrated by Novak et al.  Neutralizing antibodies against rat relaxin (MCA1) 
or control antibodies against fluoroscein (MCAF) were administered to pregnant 
Long-Evans rats. In pregnancy there is an expected rise in effective renal plasma 
flow (ERPF) and glomerular filtration rate (GFR) of between 30 and 80%. This did 
not occur in the rats that received the neutralizing MCA1 (ie the relaxin 
neutralizing antibody). The usual decreases in plasma osmolality and sodium 
concentration found during pregnancy were also inhibited by the MCA1 antibody. 
Relaxin therefore plays a central role in fluid homeostasis (Novak et al, 2001) 
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1.11 RELAXIN AND VASCULAR ENDOTHELIAL GROWTH FACTOR. 
 
The actions of relaxin in pregnancy have been well documented. By inhibiting 
collagen synthesis and promoting collagen breakdown through increased synthesis 
of collagenase, relaxin facilitates enlargement of the uterus, abdomen and breasts 
and loosens the pelvic ligaments. It is also thought to mediate blood vessel dilation, 
both in pregnancy and during the menstrual cycle. (Unemori et al, 1999).  
 
The importance of relaxin in early pregnancy centres on the induction of 
expression of an angiogenic agent, vascular endothelial growth factor (VEGF).  
This suggests that relaxin may be involved in the preparation of the endometrium 
for nidation. The evidence for the induction of VEGF by relaxin expression is 
supported clinically. In a recent trial investigating relaxin as a potential anti-
fibrotic agent for the treatment of systemic sclerosis, (Seibold et al, 2000), the 
most commonly reported side effect of treatment, was menorrhagia. This in 
keeping with the hypothesis that relaxin mediates neovascularization of the 
endothelial lining. 
 
Furthermore, relaxin is also responsible for stimulating ischaemic wound healing 
by increasing blood flow through vasodilation and angiogenesis. Rats were infused 
subcutaneously with recombinant human relaxin.  Fluid and cells collected from 
the wounds were analysed for VEGF and basic fibroblast growth factor (bFGF); 
 67 
another angiogenic agent. Expression of both factors was increased at wound sites 
in relaxin-treated rats compared with control rats (Arnold et al, 2000). 
 
Another action of relaxin may also be responsible for the increase in menstrual 
blood flow mentioned above. In a study of platelet function, preincubation of 
human platelets with relaxin resulted in a significant, concentration dependent, 
inhibition of platelet aggregation. This was accompanied by an elevation of 
intraplatelet cGMP and a decrease in the rise of cytosolic calcium levels. Its effects 
appeared to be mediated through nitric oxide. This antiaggregatory property of 
relaxin suggests that it may play a role as an antithrombotic agent. (Bani et al, 
1995). 
 
Hypertension affects 10-15% of the adult population leading to structural 
remodeling of the left ventricular myocardium and eventually heart failure. Cardiac 
fibrosis is a hallmark of hypertensive heart disease and interferes with with normal 
structure and function of myocardium. Cardiac fibroblasts are activated and 
differentiate into myofibroblasts after cardiomyocyte death, inflammation 
enhanced workload, hypertrophy and stimulation by a number of hormones (e.g. 
angiotensin II), cytokines (e.g. interleukin-1) and growth factors (e.g. transforming 
factor- β [TGF-β]. 
 
Renal fibrosis is another major complication associated with the development and 
progression of hypertension. Collagens accumulate around renal resistance vessels, 
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glomeruli and interstitium which contributes to remodeling and progression of 
renal injury. Relaxin has been shown to reduce collagen synthesis, increase 
expression of matrix metalloproteinases (MMPs) to degrade collagen and 
antagonize the influence of pro-fibrotic factors. 
 
Lekgabe et al, investigated the antifibrotic effects of relaxin on cardiac and renal 
fibrosis. (Lekgabe et al, 2005). They studied spontaneously hypertensive rats 
(SHR) and normotensive Wistar-Kyoto rats (WKY). They found that over a 14 day 
period, H2 relaxin significantly reduced the elevated collagen content in the left 
ventricle and kidney, in particular types I, II and V collagen. In addition to this, H2 
relaxin inhibited fibroblast proliferation and differentiation and induced a 
significant rise in MMP-2 expression. The authors conclude that since relaxin 
reverses cardiac and renal fibrosis that it may have therapeutic potential in 
hypertensive disease. 
 
 
1.12 SUMMARY OF THE ACTIONS OF THE RELAXIN FAMILY 
PEPTIDES. 
 
Knowledge of the relaxin family peptides and their receptors with their actions is 
developing at a rapid pace. Figure 1.4 below summarises what is currently known 
of the tissue localisation of the relaxin family peptides, their receptors and their 
functions.  Adapted from van der Westhuizen et al, 2008. 
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Figure 1.4  Relaxin family peptides, their receptors and their functions. 
 
van der Westhuizen et al, 2008 
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1.13 THE MECHANISM OF ACTION OF RELAXIN. 
 
Although there has been a great deal of work demonstrating the mechanism of 
action of relaxin in animals, little is known of its mechanism of action in humans. 
 
1.13.1 Relaxin and Nitric Oxide. 
 
The mechanism of action of relaxin appears to involve the stimulation of the 
biosynthesis of nitric oxide (NO), a gaseous free radical and potent endogenous 
vasodilator. Under physiological conditions, the vasodilatory action of NO is 
thought to be primarily an endothelium-dependent process. Endothelial cells 
constitutively express a Ca 2+ / calmodulin-dependent isoform of NOS (NOS III or 
eNOS) that continuously produces small amounts of NO, involved in a moment-to-
moment regulation of the vascular tone. Endothelial cells also express the 
inducible, high- yield NO synthase isoform (NOS II or iNOS), which synthesizes 
greater amounts of NO than NOS III and can be up-regulated by different stimuli, 
especially inflammatory cytokines and mediators. 
Relaxin generates nitric oxide in experimental animals. Bani et al examined 
vascular smooth muscle cells (VSMCs) cultured from bovine aorta. VSMCs were 
incubated with relaxin at concentrations ranging from 1nmol/l to 1 µmol/l. The 
choice of VSMCs of bovine origin was motivated by the fact that these cells retain 
a distinct muscular phenotype in in vitro culture, including the ability to produce 
nitric oxide (Mollace et al, 1991). Porcine relaxin has been found to be active in 
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cattle heifers in vivo (Musah et al, 1986). NOS activity was determined in cell 
homogenates by measuring the conversion of [3H]L-arginine to [3H]L-citrulline. 
Nitric oxide production was determined by measuring the accumulation of nitrite, 
the stable end product of nitric oxide, in bovine aortic smooth muscle cell 
(BASMC) supernatants. Relaxin was found to increase the expression and activity 
of inducible nitric oxide synthase (iNOS), nitric oxide production and intracellular 
concentrations of cyclic GMP. The addition of the NOS inhibitor L-NMMA (Nω-
monomethyl-L-arginine) abolished the effect of relaxin. This shows that relaxin 
directly activates the L-arginine-NO pathway in bovine arterial SMCs in culture. 
Relaxin was also noted to induce changes in cell shape and the actin cytoskeleton 
that are consistent with cell relaxation. (Bani et al, 1998).   
 
Relaxin has also been shown to upregulate inducible nitric oxide synthase 
expression and nitric oxide generation in vitro in rat coronary endothelial (RCE) 
cells (Failli et al, 2001). RCE cells were isolated from Wistar rat hearts and 
incubated in the presence or absence of relaxin (60ng/ml) Evaluation of nitric 
oxide production was performed by measuring the accumulation of nitrite, a stable 
end product of nitric oxide, in the supernatant of the RCE cells.  Expression of NO 
synthase isoenzymes II and III was analyzed by immunocytochemistry. The 
immunostained RCE cell cultures were examined. The control cells were almost 
negative for NOS II but showed a clear-cut cytoplasmic immunoreactivity for NOS 
III. A 24 hour incubation with relaxin caused a marked increase in the 
immunoreactivity for NOS II, whereas the immunoreactivity for NOS III was not 
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affected substantially. Since relaxin does not seem to influence NOS III isoform in 
RCE cells, the authors suggest that NOS II contributes the major amounts of 
biologically active NO in response to relaxin. The relaxin induced increase in 
coronary flow in experimental animals is also felt to be nitric oxide dependent  
(Bani Sacchi, 1995). More recently, Bani’s group demonstrated that relaxin 
potentiates the expression of iNOS (or NOS II) by endothelial cells from human 
umbilical vein in in vitro culture (Quattrone et al, 2004). Relaxin treated cells 
showed an increased expression of NOS II, attaining a maximum with 1000ng/ml 
relaxin, which gave rise to increased NO generation, as shown by nitrite assay. 
This effect of relaxin appears to be mediated by activation of NOS II transcription 
factor NF-kappaB, since it was abolished by the NF-kappaB inhibitors curcumin-
95 and dexamethasone. At variance with NOS II, the constitutive NOS III isoform 
appears unchanged upon relaxin treatment. Relaxin can therefore influence human 
umbilical vein endothelial cells (HUVEC) by up-regulating the expression of 
inducible NOS II mRNA and protein and in this respect, HUVEC behave similarly 
to bovine vascular smooth muscle cells and rat coronary endothelial cells. 
 
Danielson et al found that the relaxin induced renal vasodilatation in both male and 
female Long Evans rats was likely to be nitric oxide dependent. Their study has 
been described previously in section 1.5.2 on renal arteries (Danielson et al, 1999). 
The renal vasodilation and hyperfiltration in the relaxin-treated rats observed on 
day 5 of the infusion was completely abolished by the infusion of Nω-nitro-L-
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arginine methyl ester (L-NAME), a substrate competitive inhibitor of NO synthase, 
which was administered intravenously by infusion pump. 
 
Novak et al, investigated the effect of relaxin, on the myogenic reactivity in rat 
renal arteries (section 1.5.3), and also tried to gain mechanistic insight. Thus 
myogenic reactivity was investigated following pretreatment of the small renal 
vessels with the NO synthesis inhibitor NG-nitro-L-arginine methyl ester (L-
NAME) at 0.25mmol/l for 15 minutes. Relaxin treatment decreased myogenic 
reactivity but in the presence of L-NAME, the myogenic reactivity of relaxin-
treated rat arteries was significantly increased (to the same response as vehicle-
treated rats). 
 
1.13.2 Relaxin and ANP 
 
Relaxin has been reported to increase atrial natriuretic peptide (ANP) secretion, a 
peptide hormone involved in the regulation of blood pressure and fluid balance. 
ANP is synthesized and secreted predominantly by the atria of the adult 
mammalian heart. Toth et al, investigated the effect of relaxin on the isolated 
perfused spontaneously beating rat heart. A cyclic adenosine monophosphate 
(cAMP) dependent protein kinase inhibitor (H-89) was found to substantially 
reduce the ANP secretory effect of relaxin and a calcium/calmodulin dependent 
protein kinase inhibitor (KN-62) was found to decrease the positive chronotropic 
effect of relaxin. Both of these observations were statistically significant 
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(p<0.001). The ANP secretory and chronotropic effects of relaxin were thought to 
involve activation of protein kinase C since administration of the protein kinase C 
inhibitor staurosporine at a concentration of 30nM completely blocked the effect of 
relaxin (10nM) on immunoreactive ANP (IR-ANP) secretion (p<0.001) and heart 
rate (p<0.001). The ANP secretory and chronotropic effects of relaxin in rats 
appear to be mediated by intracellular signal transduction pathways. (Toth et al, 
1996).  
 
 
1.13.3 Relaxin and NO-cGMP and cAMP Pathways. 
 
Nitric oxide is generated in the vascular endothelium from L-arginine by a 
calcium-dependent NO synthase. Nitric oxide activates the soluble guanylate 
cyclase of the vascular smooth muscle, which increases intracellular cyclic 
guanosine monophosphate (cGMP) concentration, thus causing smooth muscle 
relaxation. 
 
The vasodilatory effect of relaxin on the pregnant rat uterine artery has previously 
been described (section 1.5.5). Longo et al, investigated the mechanism of action 
of relaxin by using three inhibitors to examine the second-messenger systems 
involved. Therefore, relaxin effects in segments of uterine arteries were studied 
after preincubation for 30 minutes with, the NO synthetase inhibitor, Nω-nitro-L-
arginine methyl ester (L-NAME 10-4 mol/l), the soluble guanylate cyclase 
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inhibitor, 1H-oxadiazolo-qui-noxaline-1-one (ODQ, 10-5 mol/l) or the adenylate 
cyclase inhibitor, 9-tetrahydro-2-furanyl-9-H-purin-6-amine (SQ-22,536,10-5 
mol/l). L-NAME, ODQ and SQ-22,536 all decreased responses to relaxin in 
uterine artery rings in mid-pregnant rats. Blockade of the NO synthase with L-
NAME or of soluble guanylate cyclase with ODQ caused a significant inhibition of 
the relaxant effect of relaxin. This suggests that the NO-cGMP pathway is one of 
the second messenger systems that mediates the vascular effects of relaxin in 
pregnancy in rats. Inhibition of the adenylate cyclase, the enzyme responsible for 
the production of cAMP, with SQ-22,536 decreased the response of the uterine 
arteries to relaxin, suggesting that cAMP is also involved in the vascular effects of 
relaxin in pregnancy (Longo et al, 2003). 
 
The molecular mechanism of the anti-anaphylactic action of relaxin previously 
discussed (section 1.6.5) appeared to involve an up-regulation of the NO 
biosynthetic pathway. Upon perfusion with relaxin, the release of nitrite (the stable 
end product of NO metabolism) increased in the perfusates. In addition, relaxin 
treatment caused an increase in the expression of iNOS protein and in the activity 
of NOS. Tissue levels of cGMP were also increased by treatment with relaxin. 
(Masini et al, 2002). 
 
It should be noted that the work described in section 1.9, above, has focused on the 
mechanism of action of relaxin in animals. As part of my MD thesis, I investigated 
the mechanism of action of relaxin in humans. 
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Aims and Hypothesis 
 
The aim is to characterise the actions and potency of relaxin in human arteries and 
veins, of various calibre, ex vivo  using concentrations similar to those found in the 
plasma in physiological (non-pregnant, pregnancy) and pathophysiological 
(chronic heart failure) states.  I will study the mechanism of action of relaxin. In 
addition, I will study the heart’s possible secretion and extraction of relaxin and 
determine whether relaxin is of prognostic importance in heart failure. The 
hypothesis is that relaxin is a circulating hormone that has measurable vascular 
effects at biological concentrations and that these actions are of potential benefit in 
cardiovascular disease. 
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CHAPTER 2: 
METHODS. 
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SUMMARY 
 
My thesis was funded by a British Heart Foundation project grant (Project number 
2001/147). In this chapter there will be a detailed description of the methods used 
for each of the studies that comprise the M.D. thesis.  
 
ETHICS 
 
Ethics approval was obtained for all the studies performed in this thesis from the 
West Ethics Committee of the North Glasgow Hospitals University NHS Trust. 
Written informed consent was obtained from all the subjects. 
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2.1 METHODS FOR STUDY OF EFFECT OF RELAXIN ON SMALL 
HUMAN RESISTANCE ARTERIES FROM THE SYSTEMIC AND 
PULMONARY CIRCULATIONS. 
 
2.1.1 PATIENTS 
 
The University of Glasgow is located adjacent to the Western Infirmary, Glasgow 
which is a large tertiary referral healthcare centre. Patients attending the cardiology 
and cardiothoracic departments of the Western Infirmary were asked to participate 
in the study.  
Gluteal biopsies taken from patients with coronary heart disease but normal left 
ventricular systolic function provided the source of the small resistance arteries 
(SRA) from the systemic circulation. All patients with renal failure (creatinine>200 
µmol/l) and diabetes mellitus were excluded from the study. 
Lung tissue obtained from patients undergoing pneumonectomy for cancer provided 
the source of the small resistance arteries from the pulmonary circulation. 
The technique of gluteal biopsy has been used for many years by our research 
group as a source of SRA. (Hillier et al, 1999; Coats et al, 2001; Petrie et al, 2001).  
Patients attended the Clinical Investigations Research Unit of the Department of 
Medicine and Therapeutics. Transport was provided. Clinical details such as 
smoking history, past medical history of myocardial infarction or hypertension and 
current medication were noted.  
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2.1.2 MATERIALS 
 
Relaxin was gifted by Connetics Corporation, Palo Alto, USA.  Many thanks to Dr 
Elaine Unemori for this gift. 
 
 
Experiments were carried out in physiological salt solution (PSS) with the 
following composition (mM): NaCI 118.4, KCI 4.7, MgSO4H2O 1.2, KH2PO4 1.2. 
Na HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2 / 95% O2 mixture.   
A Mulvany-Halpern four-channel wire myograph (Danish Myotech, Aarhus, 
Denmark) was used.  
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2.1.3   SYSTEMIC RESISTANCE ARTERY STUDIES 
 
2.1.3.1 Gluteal Biopsy Procedure and Artery Preparation 
 
Small resistance arteries (SRA) are those blood vessels which contribute the 
greatest resistance to blood flow, and are therefore most involved in regulating 
blood flow and capillary pressure (Mulvany and Aalkjaer, 1990). These arteries 
can be readily obtained from gluteal biopsies in humans. Resistance arteries are 
those blood vessels which contribute the greatest resistance to blood flow, and are 
therefore most involved in regulating blood flow and capillary pressure (Mulvany 
and Aalkjaer 1990). SRA wire myography is an in vitro technique which allows 
resistance arteries with a diameter of 100 – 500µm to be studied under precise and 
standardised conditions. Use of this technique yields information on the contractile 
or relaxant properties, and morphology, of SRA under isometric tension (Mulvany 
and Aalkjaer 1990; Mulvany and Halpern 1977). In the present investigation, 
functional studies were undertaken with SRA because of the physiological 
importance of these blood vessels. Wire myography was employed for these 
studies because this is an established technique in our laboratory (Hillier et al 
1999, 2001a; Padmanabhan et al 1999; Petrie et al 2001), in which several arteries 
may be studied at any one time, using one or more protocols. 
The gluteal biopsy was performed by myself under local anaesthetic. 10mls of 1% 
lidocaine was injected into the upper, outer quadrant of the buttock using an aseptic 
technique. Usually the right buttock was used. However if a patient had had a 
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gluteal biopsy performed previously by another research fellow for their study, 
then the left buttock was used instead. An incision was made with a scalpel and a 
gluteal biopsy (around the size of a 10 pence coin) was taken. Three to four non-
absorbable sutures were then used to close the skin and a dressing was placed on 
the skin over the sutures. Patients were asked to return to the research unit one 
week later to have the sutures removed by the research nurse. Again, transport was 
provided for this. There were no complications from this procedure. 
The biopsy was placed in a universal container in cold 0.9% sodium chloride 
solution and sent by taxi to Caledonian University for dissection of the resistance 
arteries found within the gluteal biopsy. This was performed by Fiona Johnston, 
Research Technician under the guidance of Dr Chris Hillier. Isolating SRA within 
the biopsy requires careful dissection using surgical grade instruments with the aid 
of a high power microscope. The biopsy was placed in a Petri dish filled with ice 
cold Krebs buffer, which was regularly changed during the dissection process. 
Dissection of the SRA can take several hours. 
Once dissection of the biopsy was complete, the SRA were placed in a universal 
container and stored at 4oC in a refrigerator overnight. Storage of resistance 
arteries in this way has been previously demonstrated to have no effect on the 
vasoactive properties of these blood vessels (McIntyre et al, 1998).  
 A single biopsy may yield several blood vessels (average 2 – 4).  Isolated SRA 
were divided into segments approximately 2mm long. When possible, four 
resistance arteries, were carefully mounted on two 40-µm-diameter stainless steel 
wires and mounted in the bath of a 4-channel myograph (Halpern & Mulvany, 
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Danish Myotech, Aarhus, Denmark), in which the wires are attached to a force 
transducer and micrometer, respectively.  The bath contained physiological salt 
solution (PSS), which gives a pH of 7.4 when gassed with a 5% CO2/95% O2 
mixture and pre-heated at 37°C. These conditions were maintained for the duration 
of the experiment.  In addition, the physiological salt solution was regularly 
changed throughout the experiment. 
 
2.1.3.2 Experimental Protocol (with intact endothelium) 
 
 
After a rest period of 30 minutes, a normalisation procedure was followed for each 
artery to determine the normalised internal diameter (ID), L0, at which contraction 
is thought to be optimal, and the vessel was set to that diameter (Mulvany and 
Halpern 1977). In the present study, arteries with a normalised ID of 200 – 400µm 
were used. After a rest period of 30 minute each artery was stretched at 1 minute 
intervals to determine the passive exponential wall tension-internal circumference 
(L) relationship.  From the Laplace equation, where P=T/r (P is the effective 
pressure, T is the wall tension and r is the internal radius), the equivalent 
circumference (L100) for a transmural pressure of 100mmHg, was calculated for 
each artery by an iterative computer method. Each artery was then set to the 
normalised internal diameter, L1=0.9 ×L100/pi, at which contraction is thought to be 
optimal (Mulvany and Aalkjaer 1990; Mulvany and Halpern 1977).  
Following normalisation, the vessels were left for a further hour. They were then 
exposed to a high (123mM) concentration of potassium (KPSS, solution identical 
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to PSS except that sodium is replaced by potassium on an equimolar basis) for a 
series of 5 minute periods until repeatable maximal contractions were achieved, 
and then once to 10 µmol/L of norepinephrine (NE). After a plateau contraction 
had been attained with NE, 3 µmol/L of acetylcholine (ACh) was added to 
stimulate endothelium-dependent vasodilatation. Arteries that were unable to 
contract to either KPSS or norepinephrine or showed no relaxation to acetylcholine 
(and were therefore considered to have no functionally intact endothelium) were 
discarded. The arteries were then incubated for a further 30 minutes in Krebs 
solution prior to the commencement of the concentration-response curves (CRC) 
incorporated in the study protocol.  
 
2.1.3.3 Comparative Potency of Relaxin Compared To Other Vasodilators. 
 
Cumulative concentration response curves (CCRC) were then constructed in 
vessels pre-constricted with 10-5M norepinephrine, using substance P (a powerful 
vasodilator, 10-14M to 10-9M), epoprostenol (a moderately potent vasodilator, 10-
11M to 10-8M), atrial natriuretic peptide (ANP, a weak vasodilator, 10-11M to 10-
8M),  and relaxin (concentration range 10-13 -10-7M).  
Our research group has studied each of these comparators previously. (Hillier et al, 
1999), (Petrie et al, 2000). 
The concentration of relaxin used will cover the known physiological (pregnant, 
10-9M and non-pregnant state, 10-12M) and pathophysiological (seen in chronic 
heart failure, 10-11M) range of plasma concentrations. 
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2.1.3.4 Procedure for Removal of Endothelium and Experimental Protocol in 
De-endothelialised Vessels. 
 
We were keen to establish if the action of relaxin in SRA was endothelium 
dependent. Thus, endothelium was mechanically removed from a further set of 
vessels by gently rubbing the luminal side of the arterial wall with a human hair 
(stored in ethanol and rinsed with PSS before use). Endothelial removal was 
confirmed by the lack of relaxation to ACh.  A CCRC was then constructed with 
relaxin 10-13 to 10-7M.    
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2.1.4 PULMONARY RESISTANCE  ARTERY STUDIES. 
 
2.1.4.1 Artery Preparation. 
 
Lung tissue was placed in cold Krebs-buffer solution.  Pulmonary resistance 
arteries (diameter < 300 µm, length approximately 2mm) were dissected and 
mounted in the myograph as described above and previously (Stirrat et al, 2001). 
 
2.1.4.2 Experimental protocol. 
 
Tension was applied to vessels to give transmural pressures equivalent to 12 – 
16mmHg to simulate in vivo pressures.  Vessels were allowed to equilibrate and 
endothelial integrity was tested, as described above. CCRC were then constructed   
with relaxin 10 -15 to 10 -7  M, after preconstricting each vessel with  U46619 – a 
thromboxane A2 mimetic (norepinephrine does not induce sustained constriction 
of human pulmonary vessels).   
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2.1.5 ANALYSIS OF DATA 
 
Responses (mean + standard error of the mean [SEM]) are expressed as % 
relaxation from maximally preconstricted levels.   
 
 
2.1.5.1 Comparisons Between Relaxin and Other Vasodilators 
 
Statistical comparison of maximum responses (within the concentration range 
tested) was performed using unpaired Student’s t test and Dunnett’s post hoc test 
for multiple comparisons. Comparison of curves was by one way ANOVA for 
repeated measures (Hillier et al, 2001b, Jarajapu et al, 2001, Stirrat et al, 2001).  
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2.2 METHODS FOR THE STUDY OF THE MECHANISM OF ACTION OF 
RELAXIN IN SYSTEMIC RESISTANCE ARTERIES. 
 
 
2.2.1 PATIENTS 
 
Patients with coronary heart disease but normal left ventricular systolic function 
were studied.  All patients with renal failure (creatinine>200 µmol/l) and diabetes 
mellitus were excluded from the study. 
Patient characteristics such as smoking history and current medication were 
documented. 
 
 
2.2.2 MATERIALS 
 
Relaxin was gifted by Connetics Corporation, Palo Alto, USA.   
 
Experiments were carried out in physiological salt solution (PSS) with the 
following composition (mM): NaCI 118.4, KCI 4.7, MgSO4II2O 1.2, KH2PO4 1.2. 
Na HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2 / 95% O2 mixture.   
A Mulvany-Halpern four-channel wire myograph (Danish Myotech, Aarhus, 
Denmark) was used. 
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2.2.3 GLUTEAL BIOPSY PROCEDURE AND ARTERY PREPARATION 
 
Gluteal biopsies were obtained under local anaesthesia (1% lidocaine), as 
previously described. Resistance arteries (diameter < 300 µm, length approximately 
2mm), were dissected and mounted in the myograph. A Mulvany-Halpern four-
channel wire myograph (Danish Myotech, Aarhus, Denmark) was used. The bath 
was gassed and heated for the duration of the experiment. 
 
 
2.2.4  EXPERIMENTAL PROTOCOL (WITH INTACT ENDOTHELIUM) 
 
Experiments were carried out in physiological salt solution (PSS) with the 
following composition (mM): NaCI 118.4, KCI 4.7, MgSO4II2O 1.2, KH2PO4 1.2. 
Na HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2 / 95% O2 mixture.   
After 30 minutes rest, each artery was set to the normalised internal diameter at 
which contraction is thought to be optimal. The vessels were left for a further hour 
and then repeatedly exposed to a high potassium salt solution until reproducible 
maximal contractions were achieved.  Vessels were preconstricted with 10-5 
norepinephrine and 10-6 ACh was added to test for endothelial integrity since 
relaxin is endothelium dependent. (We have demonstrated this with a previous 
experiment detailed above, section 2.1.3.3).  
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Cumulative concentration response curves (CCRC) were constructed in vessels 
pre-constricted with 10-5M norepinephrine and relaxin (concentration range 10-13 -
10-7M).  
 
2.2.4.1 Relaxin and the Prostacyclin Pathway  
 
CCRCs to relaxin (as above) were constructed to identify the importance of 
prostacyclin – before the following incubation with the cyclooxygenase inhibitor 
indomethacin.(10 -5 M).  
 
2.2.4.2 Relaxin and EDHF 
 
Next, we studied endothelium-derived hyperpolarising factor – before and 
following incubation with apamin and charybdotoxin, (blockers of Ca 2+ activated 
K+ channels).  
 
2.2.4.3 Interaction of Relaxin with Nitric Oxide. 
 
The bulk of the data from studies in experimental animals suggest that relaxin 
exerts at least some of its vasodilator effect via nitric oxide. (Bani, 1997), (Bani et 
al, 1998), (Masini et al, 1997). We therefore studied the vasorelaxant effect of 
relaxin in small human resistance arteries in the absence and presence of nitric 
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oxide synthase (NOS) inhibitors, L- NAME (Nω-nitro-L-arginine methyl ester) and 
L-NOARG (Nω-nitro-L-arginine).  
 
2.2.4.4 Second Messengers Mediating Vasodilator Action of Relaxin. 
 
It has been suggested that the vasodilator action of relaxin is mediated via the 
second messengers cyclic GMP and cyclic AMP (Bani, 1997). We studied the 
vasodilator action of relaxin in the presence of milrinone (a cAMP 
phosphodiesterase inhibitor), zaprinast (a cGMP phosphodiesterase inhibitor) and 
ODQ, a soluble guanylate cyclase inhibitor. 
 
2.2.4.5 Relaxin and Patients taking Angiotensin Converting Enzyme (ACE) 
Inhibitors. 
 
On gaining mechanistic insight, an unexpected finding was that prior treatment with 
an ACE inhibitor substantially attenuated the vasodilator effect of relaxin. 
Consequently, all subsequent analyses were carried out separately, according to 
whether vessels had been taken from patients treated with, or not treated with, an 
ACE inhibitor.  
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2.3 METHODS FOR STUDY OF EFFECT OF RELAXIN ON HUMAN 
INTERNAL MAMMARY ARTERIES AND SAPHENOUS VEINS. 
 
2.3.1 PATIENTS 
 
Coronary artery bypass graft (CABG) surgery is a common procedure at the 
Western Infirmary, with approximately 1000 operations performed each year. 
Usually distal segments of the left internal mammary artery (IMA) and saphenous 
vein (SV) are surplus to requirement and subsequently discarded. These segments 
can thus be used for scientific research.  
Patients undergoing elective CABG for coronary artery disease were included in 
this study. These patients were invited to consent for the study prior to the CABG 
being performed. The study was fully approved by the West Ethics committee of 
the Western Infirmary, on behalf of the North Glasgow Hospitals NHS Trust. 
Clinical details were recorded from case note examination. A history of current 
cigarette smoking, hypertension (defined as either current anti-hypertensive 
medication or blood pressure >140/90 mmHg, diabetes mellitus (insulin treated or 
non-insulin treated) and hypercholesterolaemia (plasma cholesterol >5.4) were 
noted. Information on other current medication was also documented at this point. 
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2.3.2 VESSEL PREPARATION 
 
Distal segments of left internal mammary artery (IMA) and saphenous veins (SV), 
were harvested at the time of routine coronary artery revascularization surgery in 
the Cardiac Surgical Theatre Suites within the Western Infirmary, and surplus to 
requirement. The discarded distal end of the IMA (1–2 cm) and segments of SV 
(1–2 cm) were immediately taken to the laboratory in Krebs –HEPES buffer on ice. 
The blood vessels were then carefully dissected free from connective tissue under 
these conditions and divided into 4-5mm segments. The vessels were then 
incubated in Krebs buffer at pH 7.4 + 2 and maintained in atmospheric conditions 
(PO
 2 19 + 4 kPa; PCO 2 3 + 4 kPa) at 37oC. 
 
2.3.3 ORGAN BATH STUDIES 
 
Some rings were studied immediately, others were stored in PSS overnight. The 
PSS (pH 7.490.1) had the following composition (in mM): 130 NaCl, 4.7 KCl, 14.9 
NaHCO3 , 1.18 KH2 PO4 , 5.5 glucose, 1.17 MgSO4 .7H2 O, 1.6 CaCl2 .2H2 O, 
and 0.03 CaNa2 EDTA. Storage under these conditions had no effect on endothelial 
responses. The vessels were cleaned of connective tissue and cut into 2–3 mm long 
segments. Rings were suspended on wires in 10 ml organ chambers filled with 
physiological salt solution (PSS), maintained at 37°C, and aerated with a mixture of 
95% O2 -5% CO2 . The rings were connected to force transducers, and changes in 
isometric tension were recorded.  
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The rings of human IMAs and SVs were equilibrated in the organ baths in PSS 
solution before the protocol was initiated. Optimal tension, defined as the tension at 
which maximum constriction to phenylephrine (PE) occurred, was determined.  
In the series of experiments, cumulative dose-response curves to phenylephrine (10 
-8
 -10 -5 M ITA, 10 -8 -10 -5 M SV) were constructed. Baths were washed out and 
the tissues allowed to relax. They were then constricted to their individual EC50 
values for phenylephrine and relaxation to carbachol (10 -8 – 10 -5 M) studied. 
Following normalisation, the vessels were left for a further hour. Potassium 
chloride (KCl) was used as a receptor-independent vascular smooth muscle cell 
depolarizing agent. At 100mmol/L, maximal contraction is obtained. The 
noradrenaline analogue PE was used to constrict the rings via α-adrenoceptors. 
Carbachol, a stable analogue of acetylcholine, was used to relax the rings in an 
endothelium-dependent manner via muscarinic receptors, resulting in stimulated 
NO release. After a plateau contraction had been attained with PE, the vessels were 
incubated for a further 30 minutes in PSS solution prior to the commencement of 
the concentration-response curves (CRC) incorporated in the study protocol. 
Arteries that were unable to contract to either KPSS or phenylephrine were 
discarded.  
 
Cumulative vasorelaxation curves to relaxin 10-13M to 10-7M were constructed in 
rings preconstricted with phenylephrine. Since relaxin is endothelium dependent, 
the calcium ionophore A23187 (CaI) was added to the bath following the CRC. A 
vasorelaxant response of the vessel to CaI (10-4M to 10-2M) confirmed that the 
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endothelium was intact (as CaI is also endothelium dependent). If there was no 
vasorelaxation response to CaI then we concluded that the endothelium was not 
functionally intact and the vessel was not included in the data. 
 
 
2.4 METHODS FOR THE STUDY OF THE PROGNOSTIC EFFECT OF 
RELAXIN COMPARED WITH NT-BNP IN PATIENTS WITH HEART 
FAILURE. 
 
2.4.1 PATIENTS 
 
Patients taking part in a randomised controlled trial of specialist nurse intervention 
were studied (Blue et al, 2001). Patients admitted to hospital, as an emergency, with 
heart failure due to left ventricular systolic dysfunction were enrolled in a trial 
comparing conventional care to conventional care supplemented by specialist heart 
failure nurse intervention.  Patients were followed for a mean of 12 months after 
randomisation.  Deaths and hospital re-admissions were recorded.  Re-admissions 
were adjudicated by a blinded end-point Committee.  The primary end-point was 
death or readmission with heart failure.  Patients consented to have venous blood 
collected for measurement of neurohumoral factors. 
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2.4.2 ASSAYS 
 
2.4.2.1 NT-pro BNP Assay 
NT-pro BNP was measured in blood samples using a validated and commercially 
available immunoassay (Roche Diagnostics, Germany).  
The Roche Elecsys proBNP (Roche Diagnostics, East Sussex, England) 
Immunoassay was used to analyse NT-proBNP (proBNP).   The Elecsys method 
used was an electrochemiluminescent immunoassay on an Elecsys 2010 
autoanalyser.  This has a within-assay and between-assay confidence variable of 2.7 
and 3.2% respectively.  The measuring range of the assay is 5 – 35,000 pg/ml.  The 
analytical sensitivity of the assay is 5pg/ml.  The diagnostic information quotes the 
cut-off for patients younger than 75 years to be 125 pg/ml and 450pg/ml for those 
75 years and older.  From work conducted on a healthy population, the following 
95th percentile figures were established as normal ranges dichotomised for age and 
sex (Table 2.1).  An elevated NT-proBNP was taken to be a value greater than the 
95th percentile for each age and sex category.     
 
Table 2.1 95th percentile according to age and sex of NT-proBNP for a 
healthy population   
 
 NT-proBNP concentration pg/ml 
Age (years) ≤ 64 65-69 70-74 ≥ 75 
Female 213.4 314.2 338.5 355.3 
Male 122.6 112.6 236 295.7 
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2.4.2.2 Relaxin Assay 
 Plasma relaxin was determined using an ELISA kit (Immundiagnostik, Bensheim, 
Germany). The polyclonal antibody was raised in rabbits. The kit has a detection 
limit of 0.40 pg/ml that was calculated from the mean optical density of the zero 
standard (measured in duplicate), plus 2 standard deviations. The intra-assay 
coefficient of variation is 9.6% (=18, at 15 pg/ml) and the interassay coefficient of 
variation is 10.2% (=12, at 15 pg/ml). The kit is highly selective for human relaxin 
with cross-reactivity measuring 100% for the H1 form and 100% for the H2 form. 
Cross-reactivity against insulin, insulin-like growth factors, luteinising hormone 
(LH), follicle stimulating hormone (FSH), and prolactin is less than <0.01%. 
  
2.4.3 STATISTICAL ANALYSIS   
 
Event rates were compared for patients with plasma concentrations of NT-pro BNP 
and relaxin above and below the group median.  As NT-pro BNP concentrations 
above the median were associated with a significantly worse clinical outcome, 
multivariate analyses were carried out in order to determine whether or not NT-pro 
BNP was an independent predictor of outcome (death and death or hospital 
admission for CHF).  Firstly, a univariate analysis was performed using all relevant 
baseline data (e.g. age, sex, NYHA Class, left ventricular function, heart rhythm, 
co-morbidity, history of prior CHF hospitalisation, creatinine etc) and variables 
significantly (p<0.05) associated with outcome were then examined in a stepwise 
multivariate analysis.   
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2.5 METHODS FOR THE STUDY OF THE TRANSPULMONARY AND 
TRANSCARDIAC GRADIENTS OF RELAXIN. 
 
2.5.1 PATIENTS 
 
20 consecutive patients undergoing elective coronary artery revascularization 
surgery for coronary artery disease, at the Cardiac Surgical Theatre Suites, within 
the Western Infirmary, were studied.  These patients were invited to consent for the 
study prior to the CABG being performed. The study was fully approved by the 
West Ethics committee of the Western Infirmary, on behalf of the North Glasgow 
Hospitals NHS Trust. 
Clinical details were recorded from case note examination. A history of current 
cigarette smoking, hypertension (defined as either current anti-hypertensive 
medication or blood pressure >140/90 mmHg, diabetes mellitus (insulin treated or 
non-insulin treated) and hypercholesterolaemia (plasma cholesterol >5.4) were 
noted. Information on other current medication was also documented at this point. 
Left ventricular systolic function (estimated ejection fraction) as determined by 
Simpson’s biplane method on echocardiography was noted for each patient. 
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2.5.2 BLOOD SAMPLING 
 
Immediately prior to institution of cardiopulmonary bypass, blood samples were 
taken by the operating Cardiothoracic Surgeon, in rapid succession, from the aorta, 
coronary sinus, pulmonary artery and pulmonary vein. I then placed the samples 
into chilled tubes and transported them directly to the lab for analysis. 
 
2.5.3 ASSAYS 
 
A validated relaxin immunoassay was used (Immundiagnostik, Bensheim, 
Germany) as detailed previously (section 2.4.2). 
 
2.5.4 STATISTICAL ANALYSIS 
    
Statistical analysis was performed using a Wilcoxon signed rank test. 
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CHAPTER 3: 
THE COMPARATIVE VASODILATOR ACTION 
OF RELAXIN IN HUMAN RESISTANCE AND 
PULMONARY ARTERIES 
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3.1 Summary  
 
It has been shown recently that relaxin is secreted by the heart. Cardiac mRNA 
expression and secretion of relaxin are increased in chronic heart failure. 
Circulating concentrations of relaxin are also markedly elevated in heart failure 
in proportion to clinical severity. (Dschietzig et al, 2001).  As with other 
peptides, such as atrial natriuretic peptide and brain natriuretic peptide, cardiac 
relaxin secretion may be a compensatory response in heart failure and relaxin 
may be a circulating vasoactive hormone. This study examined the effects of 
relaxin in small resistance arteries from the systemic and pulmonary circulations. 
 
3.2 PATIENTS 
 
Thirteen patients with coronary heart disease but normal left ventricular systolic 
function were studied.  Lung tissue was obtained from another 5 patients 
undergoing pneumonectomy for cancer. 
The study had Ethics Committee approval and patients gave informed consent. 
 
3.3 MATERIALS 
 
Relaxin was gifted by Connetics Corporation, Palo Alto, USA.  Experiments 
were carried out in physiological salt solution (PSS) with the following 
composition (mM): NaCI 118.4, KCI 4.7, MgSO4II2O 1.2, KH2PO4 1.2. Na 
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HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2/95% O2 mixture.  A Mulvany-Halpern four-channel wire 
myograph (Danish Myotech, Aarhus, Denmark) was used.  
 
3.4 SYSTEMIC RESISTANCE ARTERY STUDIES 
 
3.4.1 Gluteal biopsy procedure and artery preparation 
Gluteal biopsies were obtained under local anaesthesia (1% lidocaine), as 
previously described (Methods 2.1.3). Resistance arteries (diameter < 300 µm, 
length approximately 2mm), were dissected and mounted in the myograph as 
previously described. The bath was gassed and heated for the duration of the 
experiment. 
 
3.4.2 Subjects 
Table 3.1 shows the characteristics of the patients studied.  
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Table 3.1. Characteristics of Patients Providing Small Systemic Resistance 
Arteries 
Number of patients 13 
Sex M/F 8/5 
Age, y (range) 67 (55-78) 
Previous MI 4 
Previous CABG 6 
Current smoker 3 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
11 
13 
13 
6 
2 
4 
3 
5 
2 
Creatinine, µmol/L 
Mean LVEF % (range) 
105+ 5 
55 (45-70) 
 
M/F indicates male/female; MI indicates myocardial infarction; CABG, coronary 
artery bypass grafting; ACE, angiotensin-converting enzyme, HMG CoA, 3-
hydroxy-3-methylglutaryl coenzyme A, LVEF, left ventricular ejection fraction. 
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3.5 STUDIES IN SMALL SYSTEMIC RESISTANCE ARTERIES WITH 
INTACT ENDOTHELIUM 
 
3.5.1 Resistance artery diameter 
The mean internal diameter (ID) of the systemic resistance arteries was 283 + 21 
µm.  ACh caused an 88+ 4% reduction in norepinephrine-induced tone, verifying 
the existence of an intact endothelium. 
 
         3.5.2 Response to vasodilators 
Figure 3.1 below shows the vasodilator activity of substance P (n=8), epoprostenol 
(PGI 2) (n=6), ANP (n=6) and relaxin (n=8).  
 
 105
0
20
40
60
80
100
-14 -13 -12 -11 -10 -9 -8 -7 -6
LOG [AGONIST] M
%
 
RE
LA
XA
TI
O
N
RELAXIN n=8
ANP n=6
SUBSTANCE P n=8
PGI 2 n=6
 
Figure 3.1. Cumulative concentration response curves for relaxin, ANP, 
substance P and epoprostenol in small human resistance arteries with intact 
endothelium. 
 
Substance P, as noted previously, was a powerful vasodilator.   Relaxin had 
comparable activity to epoprostenol (prostaglandin I2).  ANP was the weakest of 
the vasodilators studied.   The maximal responses were 88(+5) %, 66(+16) %, 
67(+10) % and 52(+16) %, respectively.  
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A 10% of maximal vasodilator response was achieved with 1x10-13M substance P, 
2x10-13M epoprostenol, 1x10-12M relaxin and 3x10-10M ANP (P<0.05 for relaxin 
versus ANP). 
  
Figure 3.2.  Cumulative concentration response curve for relaxin compared 
with ANP in small human resistance arteries with intact endothelium. 
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P<0.05 
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3.5.3 Relaxin versus ANP 
  
We found that relaxin is vasoactive at concentrations comparable to those found 
in chronic heart failure. Mean plasma relaxin concentrations in patients with 
severe chronic heart failure, average 2.5 to 3.34 x 10-11 mol/L while mean plasma 
ANP concentrations in patients with severe CHF, average 2.5 x 10-11 mol/L. At 
10-11 mol/L relaxin caused 26% vasodilation of resistance arteries versus 0.68% 
with the same concentration of ANP. 
 
3.5.4 Procedure for removal of endothelium and experimental protocol in de-
endothelialised vessels. 
 
To gain further mechanistic insight into relaxin, endothelium was mechanically 
removed from a further set of vessels by gently rubbing the luminal side of the 
arterial wall with a human hair (stored in ethanol and rinsed with PSS before use). 
Endothelial removal was confirmed by the lack of relaxation to ACh. A CCRC 
was then constructed with relaxin 10-13 to 10-7M.    
 
3.5.5 Response to relaxin in systemic resistance arteries following removal of 
endothelium  
 
Figure 3.3 shows that endothelial rubbing virtually abolished the action of relaxin 
(n=8, p<0.05). 
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Figure 3.3 Cumulative concentration response curve for relaxin in small 
human resistance arteries with intact endothelium and after removal of the 
endothelium. 
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3.6 PULMONARY RESISTANCE  ARTERY STUDIES. 
 
3.6.1 Artery preparation. 
 
Lung tissue was placed in cold Krebs-buffer solution.  Pulmonary resistance 
arteries (diameter < 300 µm, length approximately 2mm) were dissected and 
mounted in the myograph as described in Methods 2.1.4. 
 
3.6.2 Experimental protocol. 
 
Tension was applied to vessels to give transmural pressures equivalent to 12 – 
16mmHg to simulate in vivo pressures.  Vessels were allowed to equilibrate and 
endothelial integrity was tested, as described above. CCRC were then constructed   
with relaxin 10 -15 to 10 -7 M, after preconstricting each vessel with  U46619 – a 
thromboxane A2 mimetic (norepinephrine does not induce sustained constriction 
of human pulmonary vessels). 
Table 3.2 shows the characteristics of the patients studied.   
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Table 3.2. Characteristics of Patients Providing Small Pulmonary Resistance 
Arteries 
Number of patients 5 
Sex M/F 2/3 
Age, y (range) 60 (52-66) 
Previous MI 0 
Previous CABG 0 
Current smoker 1 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
1 
0 
0 
2 
1 
1 
0 
0 
0 
Creatinine, µmol/L 106+ 3 
 
M/F indicates male/female; MI indicates myocardial infarction; CABG, coronary 
artery bypass grafting; ACE, angiotensin-converting enzyme, HMG CoA, 3-
hydroxy-3-methylglutaryl coenzyme A. 
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3.6.3 Response to relaxin in small pulmonary resistance arteries. 
 
The mean ID of the pulmonary vessels (n=5) was 208.8 +10.6µm.  ACh caused a 
76+21% reduction in agonist-induced tone yet relaxin had no effect. 
  
 
3.7 Summary of Chapter Results 
 
In small human systemic resistance arteries, relaxin is a potent vasodilator. 
The vasodilatory action of relaxin is more potent than that of ANP and equipotent 
to epoprostenol. Relaxin’s vasodilatory action, however, is less potent than that of 
substance P. In these vessels, the vasodilatory action of relaxin is endothelium 
dependent. 
In small human pulmonary resistance arteries, relaxin has no effect. 
 
 
These findings have been published.  
C Fisher, M Maclean, I Morecroft, A Seed, F Johnston, C Hillier and J McMurray. 
Is the Pregnancy Hormone Relaxin Also a Vasodilator Peptide Secreted by the 
Heart? Circulation. 2002;106:292-295. 
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CHAPTER 4: 
THE MECHANISM OF ACTION OF RELAXIN 
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          4.1 Summary 
 
Having established that relaxin is a potent, endothelium dependent, vasodilator in 
human systemic resistance arteries, I then went on, in detail, to research its 
mechanism of action.  
 
As described in Section 1.5, the endothelium is an autocrine and paracrine organ 
that produces substances that decrease vascular smooth muscle and inhibit 
inflammation and thrombosis. These substances include nitric oxide, prostacyclin 
and endothelium derived hyperpolarizing factor (EDHF). The focus of the 
experiments in this chapter, therefore, was to block each of the pathways involving 
these substances: nitric oxide, prostacyclin and EDHF, in turn. 
 
Firstly, I investigated whether manipulation of nitric oxide and cyclic GMP would 
have an affect on relaxin’s vasodilatory action. Secondly, I looked at whether 
manipulation of prostanoids and cAMP altered relaxin’s action. Lastly, I 
determined whether manipulating EDHF would have an affect on relaxin’s action. 
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4.2 PATIENTS 
 
Patients with coronary heart disease with no history of heart failure were studied.  
Details of the patients studied are given in Tables 4.1 and 4.2. For reasons 
detailed below, groups were split into those patients taking ACE inhibitors and 
those patients not taking ACE inhibitors. 
 
The study had Ethics Committee approval and patients gave informed consent. 
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Table 4.1. Characteristics of Patients Providing Small Systemic Resistance 
Arteries On an ACE Inhibitor 
Number of patients 28 
Sex M/F 22/6 
Age, y (range) 61 (44-74) 
Previous MI 11 
Previous CABG 3 
Current smoker 3 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
24 
28 
27 
28 
7 
6 
0 
5 
5 
Creatinine, µmol/L 109+ 4 
 
M/F indicates male/female; MI indicates myocardial infarction; CABG, coronary 
artery bypass grafting; ACE, angiotensin-converting enzyme, HMG CoA, 3-
hydroxy-3-methylglutaryl coenzyme A.  
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Table 4.2. Characteristics of Patients Providing Small Systemic Resistance 
Arteries Not On an ACE Inhibitor 
Number of patients 30 
Sex M/F 23/7 
Age, y (range) 62 (41-80) 
Previous MI 8 
Previous CABG 3 
Current smoker 4 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
25 
30 
26 
0 
16 
6 
0 
9 
6 
Creatinine, µmol/L 111+ 5 
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4.3 MATERIALS 
 
Relaxin was gifted by Connetics Corporation, Palo Alto, USA.  Experiments were 
carried out in physiological salt solution (PSS) with the following composition 
(mM): NaCI 118.4, KCI 4.7, MgSO4II2O 1.2, KH2PO4 1.2. Na HCO3 24.9, CaCI2 
2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when gassed with a 5% 
CO2/95% O2 mixture.  A Mulvany-Halpern four-channel wire myograph (Danish 
Myotech, Aarhus, Denmark) was used.  
 
 
4.4 GLUTEAL BIOPSY PROCEDURE AND ARTERY PREPARATION 
 
Gluteal biopsies were obtained under local anaesthesia (1% lidocaine), as 
previously described (Methods 2.1.3). Resistance arteries (diameter < 300 µm, 
length approximately 2mm), were dissected and mounted in the myograph as 
previously described. The bath was gassed and heated for the duration of the 
experiment. 
 
4.4.1 Resistance Artery Diameter 
The mean internal diameter of the human small systemic resistance arteries 
studied was 290 ± 25 µ M.  ACh caused a 90 ± 5% reduction in norepinephrine 
induced tone, verifying the existence of an intact endothelium. 
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4.5 EFFECT OF PRIOR TREATMENT WITH AN ACE INHIBITOR 
 
An unexpected finding was that prior treatment with an ACE inhibitor 
substantially attenuated the vasodilator effect of relaxin (p<0.0001) (Figure 4.1)  
 
Figure 4.1. 
Relaxin Relaxation Curve Comparing COA and CNOA 
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COA = patient on ACE inhibitor 
CNOA = patient not on ACE inhibitor 
  
Consequently, all subsequent analyses were carried out separately, according to 
whether vessels had been taken from patients treated with, or not treated with, an 
ACE inhibitor. 
The results of these analyses will be presented separately. 
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4.6 PATIENTS ON ACE INHIBITORS 
 
4.6.1 Manipulation of Nitric Oxide and cyclic GMP 
 
I) Inhibition of Nitric Oxide Synthase    
 
Both L-NOARG and L-NAME affected the vasodilator response to relaxin in 
arteries from patients treated with an ACE inhibitor. As each graph demonstrates, 
relaxin’s vasodilator action was enhanced by blocking nitric oxide. This result was 
not expected and indeed was the opposite of what was anticipated (Figures 4.2 and 
4.3). 
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Figure 4.2  
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Figure 4.3. 
Relaxin Relaxation Curve Incubated w ith L-NAME (COA)
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p<0.05 
p<0.05 
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II) Inhibition of Soluble Guanylate Cyclase  
 
Prior incubation with ODQ, the soluble guanylate cyclase inhibitor, reduced the 
vasodilator response to relaxin (Figure 4.4) in arteries taken from patients treated 
with an ACE inhibitor (Soluble guanylate cyclase converts GTP to cGMP) 
 
 
Figure 4.4. 
Relaxin Relaxation Curve w ith ODQ -4M (COA)
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p=0.0009 
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III) Inhibition of cGMP Phosphodiesterase:    
 
Prior incubation of arteries with zaprinast, which prevents the breakdown of 
cGMP, appeared to mildly enhance the vasodilator response to relaxin in patients 
treated with an ACE inhibitor (figure 4.5). 
 
 
 
Figure 4.5. 
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p<0.05 
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4.6.2 Manipulation of Prostanoids and cyclic AMP 
 
I) Inhibition of Cyclo-oxygenase   
 
Indomethacin, which inhibits cyclo-oxygenase, greatly reduced the vasodilator 
effect of relaxin in arteries obtained from patients taking an ACE inhibitor (figure 
4.6). 
 
 
 
Figure 4.6.  
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II) Inhibition of cAMP Phosphodiesterase    
 
In arteries from patients treated with an ACE inhibitor, prior incubation with 
milrinone (which prevents the breakdown of cAMP) enhanced the vasodilator 
response to relaxin (Figure 4.7). 
 
 
 
Figure 4.7. 
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4.6.3 Inhibition of Endothelium-Derived Hyperpolarising Factor 
 
Prior incubation with the EDHF inhibitors, charybdotoxin and apamin, in arteries 
from patients treated with an ACE inhibitor (Figure 4.8), enhanced the vasodilator 
response of relaxin. (Charybdotoxin and apamin block calcium activated potassium 
channels).  
 
Figure 4.8. 
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4.7 PATIENTS NOT ON ACE INHIBITORS 
4.7.1 Manipulation of Nitric Oxide and cyclic GMP 
 
I) Inhibition of Nitric Oxide Synthase  
 
Inhibition of nitric oxide synthase with L-NOARG and L-NAME reduced the 
vasodilator response to relaxin in arteries taken from patients not taking an ACE 
inhibitor (figure 4.9 and figure 4.10). 
 
Figure 4.9. 
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Figure 4.10. 
 
Relaxin Relaxation Curve w ith L-NAME (CNOA)
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II) Inhibition of Soluble Guanylate Cyclase  
  
Prior incubation with ODQ greatly reduced the vasodilator response to relaxin 
(Figure 4.11) in arteries taken from patients not treated with an ACE inhibitor. 
(Soluble guanylate cyclase converts GTP to cGMP). 
 
Figure 4.11. 
Relaxin Relaxation Curve With ODQ -4M (CNOA)
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III) Inhibition of cGMP Phosphodiesterase   
 
Prior incubation of arteries with zaprinast (which prevents cGMP breakdown) 
reduced the vasodilator response to relaxin in patients not taking an ACE inhibitor 
(figure 4.12). 
 
Figure 4.12. 
Relaxin Relaxation Curve with Zaprinast (CNOA)
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4.7.2 Manipulation of Prostanoids and cyclic AMP 
 
I) Inhibition of Cyclo-oxygenase   
 
In arteries from patients not treated with an ACE inhibitor, prior incubation with 
indomethacin reduced the vasodilator response to relaxin (Figure 4.13). 
 
Figure 4.13. 
Relaxin Relaxation Curve w ith Indomethacin (CNOA)
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II) Inhibition of cAMP phosphodiesterase   
 
In arteries from patients not treated with an ACE inhibitor, prior incubation with 
milrinone (which prevents cAMP breakdown) had no effect on the vasodilator 
response to relaxin (Figure 4.14). 
 
Figure 4.14. 
Relaxin Relaxation Curve with Milrinone (CNOA)
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4.7.3 Inhibition of Endothelium-Derived Hyperpolarising Factor 
 
Prior incubation with the EDHF inhibitors, charybdotoxin and apamin, in arteries 
from patients not treated with an ACE inhibitor, had no effect on the vasodilator 
response of relaxin (Figure 4.15). (Charybdotoxin and apamin block calcium 
activated potassium channels).  
 
Figure 4.15. 
Relaxin Relaxation Curve With Apamin + Charyb (CNOA) 
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4.8 Summary of Chapter Results 
 
4.8.1 PATIENTS ON ACE INHIBITORS 
 
1) Manipulation of prostanoids and cyclic AMP. 
 
In patients treated with an ACE inhibitor, manipulation of prostanoids and cAMP  
is important. Blocking the prostanoid pathway with indomethacin blocked 
relaxin’s vasodilatory action. By preventing the breakdown of cAMP with 
milrinone, relaxin’s vasodilatory action was enhanced. 
 
2) Manipulation of cyclic GMP  
 
Manipulation of the cyclic GMP second messenger system may be important in 
patients treated with an ACE inhibitor. By inhibiting guanylate cyclase with ODQ 
and thus the conversion of GTP to cGMP, relaxin’s vasodilatory effect was 
reduced. In keeping with this, preventing the breakdown of cyclic GMP with 
zaprinast, did enhance (although mildly) relaxin’s vasodilatory effect. However, 
these findings were at supraphysiological levels of relaxin and so may not be 
clinically relevant. 
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3) Manipulation of nitric oxide and  4) Manipulation of EDHF 
 
Manipulation of the nitric oxide pathway by blocking nitric oxide with L-NOARG 
and L-NAME and EDHF pathway by blocking potassium channels with apamin 
and charybdotoxin had curious effects, in patients taking an ACE inhibitor, by 
enhancing relaxin’s vasodilatory action which is the opposite of what one might 
expect. The results for L-NOARG and L-NAME were at supraphysiological levels 
of relaxin and may not be clinically relevant. 
 
 
4.8.2 PATIENTS NOT ON ACE INHIBITORS 
 
1) Manipulation of nitric oxide  
 
Manipulation of the nitric oxide pathway is important. In patients not treated with 
an ACE inhibitor, blocking nitric oxide synthesis with L-NAME and L-NOARG, 
resulted in reduced vasorelaxation with relaxin. 
 
2) Manipulation of cGMP  
 
Manipulation of the cGMP second messenger system by inhibiting guanylate 
cyclase (with ODQ) and thus the conversion of GTP to cGMP, is also important in 
patients not treated with an ACE inhibitor. ODQ greatly reduced relaxin’s 
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vasodilatory action. However, preventing the breakdown of cyclic GMP with 
zaprinast did not enhance relaxin’s vasodilatory effect and if anything reduced 
vasodilation. 
 
 
 
 
3) Manipulation of prostanoids and cyclic AMP 
 
Manipulation of prostanoids by blocking prostacyclin with indomethacin in 
patients not treated with an ACE inhibitor, reduced relaxin’s vasodilatory action. 
However, preventing the breakdown of cAMP with milrinone had no effect on the 
vasodilatory action of relaxin in these patients. 
 
 
4) Manipulation of EDHF 
 
Manipulation of the EDHF pathway by blocking potassium channels with apamin 
and charybdotoxin respectively had no effect on relaxin’s vasodilatory action in 
patients not treated with an ACE inhibitor.  
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CHAPTER 5: 
RELAXIN IN HUMAN INTERNAL MAMMARY 
ARTERIES AND SAPHENOUS VEINS. 
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5.1 Summary 
 
Having shown that in small human systemic resistance arteries, relaxin is a potent 
vasodilator, I was keen to establish whether the same were true in larger calibre 
arteries. Also, the action of relaxin in the venous system has not been investigated, 
previously. In this chapter, therefore, the results of this investigation into the action 
of relaxin in human internal mammary arteries (IMA) and saphenous veins (SV) 
are reported. 
 
 
5.2 PATIENTS 
 
IMA and SV from ten patients with coronary heart disease undergoing CABG 
were studied, as described in Methods 2.3.1 
 
 
Table 5.1 below gives the characteristics of the patients involved in the study. 
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Table 5.1. Characteristics of Patients Providing Internal Mammary Arteries 
and Saphenous Veins 
 
Number of patients 10 
Sex M/F 10/0 
Age, y (range) 68 (54-78) 
Previous MI 4 
Previous CABG 0 
Current smoker 1 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
8 
10 
8 
2 
8 
2 
1 
8 
5 
Creatinine, µmol/L 120+ 8 
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M/F indicates male/female; MI indicates myocardial infarction; CABG, coronary 
artery bypass grafting; ACE, angiotensin-converting enzyme, HMG CoA, 3-
hydroxy-3-methylglutaryl coenzyme A.  
 
The study had Ethics Committee approval and patients gave informed consent. 
 
5.3 MATERIALS 
Relaxin was gifted by Connetics Corporation, Palo Alto, USA.  Experiments 
were carried out in physiological salt solution (PSS) with the following 
composition (mM): NaCI 118.4, KCI 4.7, MgSO4II2O 1.2, KH2PO4 1.2. Na 
HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2/95% O2 mixture.  
 
5.4 ORGAN BATH TECHNIQUE 
 
Rings of IMA and SV were set up in organ baths as described in Methods 2.3.2. 
Cumulative response curves were then constructed to relaxin in vessels pre-
constricted with phenylephrine. Since relaxin is endothelium dependent, an intact 
endothelium was verified, following the CCRC, if relaxation to the calcium 
ionophore (CaI) A23187 occurred. If no relaxation to CaI occurred then the 
vessel was not included in the data. IMA from 12 patients and SV from 14 
patients were rejected because the endothelium was not intact. 
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5.5 RELAXIN CUMULATIVE CONCENTRATION RESPONSE CURVE 
IN HUMAN IMA 
 
In human internal mammary arteries, no significant difference was found 
between relaxin and the control (vehicle) i.e. relaxin did not cause significant 
relaxation in these large calibre arteries (Figure 5.1). 
 
Figure 5.1. 
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5.6 RELAXIN CUMULATIVE CONCENTRATION RESPONSE CURVE 
IN HUMAN LSV 
 
In human long saphenous veins, no significant difference was found between 
relaxin and the control (vehicle) i.e. relaxin did not cause significant relaxation in 
these large calibre veins (Figure 5.2). 
 
Figure 5.2. 
Relaxin Relaxation Curve for LSV
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5.7 Summary of Chapter Results 
 
Relaxin was not found to cause relaxation in human large calibre vessels i.e 
internal mammary arteries or long saphenous veins harvested at the time of 
coronary artery bypass grafting. 
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CHAPTER 6: 
RELAXIN COMPARED WITH NT-BNP IN 
HEART FAILURE 
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6.1 Summary  
 
Relaxin has been shown to be a powerful systemic arterial vasodilator released 
from the heart. (Fisher et al, 2002). One recent report has shown increased cardiac 
relaxin release and elevated plasma relaxin concentrations in heart failure. 
(Dschietzig et al, 2001).  Consequently, it has been postulated that relaxin, like the 
natriuretic peptides, may be secreted as a compensatory neuroendocrine response 
in heart failure. ((Dschietzig et al, 2001), (Fisher et al, 2002).   With other 
pathophysiologically important neurohumoral mediators there is a clear 
relationship to outcome in heart failure, whereby higher plasma concentrations, 
indicating greater neurohumoral activation, are associated with a worse 
prognosis.(Francis et al, 1984), (Cohn et al, 1984), (Swedberg et al, 1990). 
Consequently, we have examined the relationship between plasma relaxin 
concentration and clinical events in patients with chronic heart failure (CHF).  As a 
“positive control”, we also examined the prognostic importance of N-terminal pro 
B-type natriuretic peptide (NT pro BNP) in the same patients (Hunt et al, 1995). 
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6.2 PATIENTS 
 
Patients taking part in a randomised controlled trial of specialist nurse intervention 
were studied.  This trial has been described in detail elsewhere (Blue et al, 2001).  
Briefly, patients admitted to hospital, as an emergency, with heart failure due to 
left ventricular systolic dysfunction were enrolled in a trial comparing 
conventional care to conventional care supplemented by specialist heart failure 
nurse intervention.  Patients were followed for a mean of 12 months after 
randomisation.  Deaths and hospital re-admissions were recorded.  Re-admissions 
were adjudicated by a blinded end-point Committee.  The primary end-point was 
death or readmission with heart failure.  Patients consented to have venous blood 
collected for measurement of neurohumoral factors. 
Of the 165 patients randomised, plasma NT-pro BNP and relaxin concentrations 
were available in 87.   
Details of these patients are given in Table 6.1 below. 
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Table 6.1.  Characteristics of  Patients Studied  
 
Number of patients 87 
Age (range) 75(51-93) 
Sex (male/female) 51/36 
Current angina 38 
Previous MI 40 
Diabetes 13 
COPD 24 
AF 25 
Beta-blocker 9 
ACE inhibitor 37 
Diuretic 60 
HMG CoA reductase 
inhibitor 
2 
Calcium channel 
blocker 
20 
Digoxin 17 
Nitrate 12 
Aspirin 43 
Warfarin 9 
Admission NYHA class 
II 
III 
IV 
 
21 
28 
38 
Creatinine µmol/l 132+/-7.2 
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MI indicates myocardial infarction; COPD, chronic obstructive pulmonary disease; 
AF, atrial fibrillation; ACE, angiotensin-converting enzyme, HMG CoA, 3-
hydroxy-3-methylglutaryl coenzyme A and NYHA, New York Heart Association. 
 
 
 
6.3 NT-pro BNP CONCENTRATIONS DETECTED IN PATIENTS 
 
The median (range) plasma NT-pro BNP concentration was marked elevated at 
2994 (134-35,000) pg/ml compared to normal (< 334 pg/ml for females and <227 
pg/ml for males).   
Plasma NT-pro BNP was a predictor of both death or heart failure hospitalisation 
and death (Figures 6.1 and 6.2).  Of patients with NT-pro BNP above the median 
concentration (n=43), 23 (53%) died and 30 (70%) died or were hospitalised with 
CHF.  For those with NT- pro BNP concentrations below the median (n=44), these 
proportions were 5 (11%) and 12 (27%) (p<0.0001 for death, and p<0.0001 for 
death or CHF hospitalisation). 
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Figure 6.1 Time to death in patients with plasma NT pro BNP concentrations 
above and below the median 
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Figure 6.2.  Time to death or hospital admission for heart failure in patients 
with      plasma NT pro BNP concentrations above and below the median. 
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In the multivariate analysis, plasma NT pro BNP concentration was a significant, 
independent predictor of death or CHF hospitalization (odds ratio 4.15, p=0.003) 
and of death alone (odds ratio 2.22, p=0.03). Details of the univariate and 
multivariate analyses are given below. 
 
Univariate analyses 
An increased risk of death was conferred by having a plasma NT-proBNP 
concentration above the median value (OR 8.3±4.7, 95% CI 2.8,25.1; P<0.0001) or 
increasing plasma creatinine concentration (R2=0.05, P=0.04). An increased risk of 
death was also conferred by having COPD (OR 2.9±1.5, 95% CI 1.1,7.8; P=0.031), 
a history or previous hospitalisation for CHF (OR 2.6±1.2, 95% CI 1.0, 6.5; 
P=0.043). A reduced risk of death was associated with the presence of atrial 
fibrillation (OR 0.2±0.1, 95% CI 0.05, 0.7; P=0.015).  
An increased risk of death or CHF hospitalisation was associated with having a 
plasma NT-proBNP concentration above the median value (OR 8.8±4.4, 95% 
CI3.3,23.2; P<0.0001), increasing plasma creatinine concentration (R2 = 0.06; 
P=0.023), the presence of valve disease (OR 3.6±2.3, 95% CI 1.0,12.5; P=0.041). 
A reduced risk of death was associated with the presence of atrial fibrillation (OR 
0.4±0.2, 95% CI 0.1, 1.0; P=0.049). 
 
Multivariate analyses 
The results of the multivariate analyses are detailed below.  
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MULTIVARIATE ANALYSIS FOR DEATH, BASED ON FINDINGS FROM 
UNIVARIATE ANALYSES. 
Outcome variable: death (DEATH), n=87 
------------------------------------------------------------------------------ 
Covariate                 n       Odds Ratio      P>|z|  (95% Conf. Interval) 
------------------------------------------------------------------------------ 
NT-proBNP                                         
  per S.D. (=  6409) 87           2.220       0.029  (1.179 to 4.603) 
CREATININE                                      
  per S.D. (= 67.31) 87           1.110       0.745  (0.593 to 2.078) 
AF                                          
    0*                   60                1 
    1                     25           0.240       0.053  (0.057 to 1.019) 
COPD                                       
    0*                    61                1 
    1                      24           2.011       0.239  (0.628 to 6.437) 
CHFADMISSION                                      
    0*                   47                1 
    1                      38           1.926       0.263  (0.612 to 6.060) 
 
Plasma NT-proBNP was found to be an independent predictor of death (OR 2.2, 
95% CI1.2,4.6; P=0.03).  
 
MULTIVARIATE ANALYSIS FOR DEATH/CHF ADMISSION BASED ON 
FINDINGS FROM UNIVARIATE ANALYSES 
 
Outcome variable: DEATH/CHF, n=87, using standard deviation for NT-proBNP 
and CREATININE 
------------------------------------------------------------------------------ 
Covariate                    n        Odds Ratio      P>|z|  (95% Conf. Interval) 
------------------------------------------------------------------------------ 
NT-proBNP                                         
  per S.D. (=  6409)     87           4.152         0.003  (1.784 to 12.028) 
 
CREATININE                                       
  per S.D. (= 67.31)      87           1.061         0.873  (0.516 to 2.178) 
AF                                          
    0*                    60                1 
    1                      25           0.426         0.163  (0.128 to 1.415) 
VALVEDISEASE                                        
    0*                    70                1 
    1                      15           2.891         0.185  (0.601 to 13.902) 
 
NT-proBNP was an independent predictor of death/CHF hospitalisation (OR 4.152 
1.7 to 12.0; P=0.003).  
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6.4 RELAXIN CONCENTRATIONS DETECTED IN PATIENTS. 
 
The median (range) plasma relaxin concentration was also markedly elevated at 89 
(11-644) pg/ml compared to normal (< 2 pg/ml).  However, in contrast to NT pro 
BNP, there was no relationship between relaxin and outcome (Figures 6.3 and 6.4).  
Of those patients with a relaxin concentration above the median (n=42), 13 (31%) 
died and 20 (48%) died or were hospitalised.  These proportions for patients with a 
plasma relaxin concentration below the median (n=45) were 15 (33%) and 22 
(49%)  (p=0.76 for death and p=0.84 for death or CHF hospitalisation). Plasma 
relaxin concentration was not a significant predictor of outcome in the univariate 
analysis. 
There was no correlation between plasma concentrations of relaxin and NYHA 
functional class (as a marker of severity of heart failure). 
 
There was no correlation between plasma concentrations of relaxin and those of 
NT-proBNP (Figure 6.5). 
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Figure 6.3.  Time to death in patients with plasma relaxin concentrations 
above and below the median. 
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Figure 6.4. Time to death or hospital admission for heart failure in patients 
with plasma relaxin concentrations above and below the median. 
 
 
 
 
 
 155
 
Figure 6.5. Correlation plot for NT pro BNP and relaxin concentrations. 
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6.5 Summary of Chapter Results. 
 
NT-pro BNP is predictive of both death and death or readmission with worsening 
heart failure. 
We have shown that NT-pro BNP is a powerful and independent predictor of 
outcome in chronic heart failure (CHF). 
Although plasma levels of relaxin were elevated in patients with CHF, it is not 
predictive of outcome. 
 
 
 
 
 
This work has been published. 
C Fisher, C Berry, L Blue, J J Morton, J McMurray. N-terminal pro B type 
natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts 
prognosis in patients with chronic heart failure. Heart 2003; 89:879-881. 
 
 
 
 
 
 
 157
 
 
 
 
 
 
CHAPTER 7: 
TRANSPULMONARY AND TRANSCARDIAC 
GRADIENT OF RELAXIN 
 
 
 
 
 
 
 
 
 
 158
7.1 Summary 
 
Relaxin has only lately been shown to have renal and haemodynamic actions.  
Relaxin  may also be secreted by the heart, at least when it is failing (Dschietzig 
et al, 2001) Plasma relaxin concentrations are elevated in chronic heart failure 
(CHF) and myocardial expression of the H1 and H2 relaxin gene is increased in 
proportion to the severity of CHF.  Whether the heart is a source of relaxin when 
cardiac contractility is preserved is unknown.  The lungs are commonly involved 
in the clearance or secretion of vasoactive peptides but their role in relaxin 
metabolism is unknown.  The aim of this study was to measure trans-cardiac and 
trans-pulmonary relaxin gradients in subjects with preserved left ventricular 
ejection fraction (LVEF).  Patients undergoing coronary artery bypass grafting 
(CABG) were studied as both pulmonary and cardiac arterial inflow and venous 
effluent can be readily sampled. 
Our study had Ethics approval. 
   
7.2 PATIENTS 
20 consecutive patients were studied.  Immediately prior to institution of 
cardiopulmonary bypass, blood samples were taken into chilled tubes, in rapid 
succession, from the aorta, coronary sinus, pulmonary artery and pulmonary vein. 
A validated relaxin immunoassay was used (Immundiagnostik, Bensheim, 
Germany). Statistical analysis was performed using a Wilcoxon signed rank test. 
Patient characteristics are shown in Table 7.1 below. 
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Table 7.1. Characteristics of Patients Studied. 
male/female (n=14/6) 
 
mean age (range) 62 (44 – 74) 
 
mean LVEF % (range) 55 (25 – 70) 
 
medical history 
• hypertension 
• diabetes mellitus 
• prior MI 
• asthma 
 
4 
3 
7 
2 
 
current smoker 3 
 
medication 
• beta-blocker 
• ACE inhibitor 
• CCB 
• long acting nitrate 
• nicorandil 
• HMG CoA reductase 
inhibitor 
• diuretic 
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CCB    = calcium channel blocker 
HMG CoA  = 3-hydroxy-3-methylglutaryl coenzyme A 
LVEF    = left ventricular ejection fraction 
  
 
 
 
7.3 RESULTS. 
 
7.3.1 Transcardiac Gradient of Relaxin. 
 
There was a decrement in the concentration of relaxin between aorta and coronary 
sinus in 16 of the 20 subjects studied, suggesting cardiac extraction of relaxin.  
The mean (SD) concentration fell from 38.1(61.3) to 32.8(57.8) pg/ml (p<0.04).   
No characteristic differentiated the 16 patients with cardiac extraction of relaxin 
from the remaining four (Figure 7.1). 
 
7.3.2 Transpulmonary Gradient of Relaxin. 
 
There was no trans-pulmonary gradient in relaxin concentration.  The mean (SD) 
concentration in the pulmonary artery was 42.0 (68.3) pg/ml versus 41.8(69.1) 
pg/ml in the pulmonary vein (p=n.s). (Figure 7.2). 
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7.4 Summary of Chapter Results. 
 
In patients with coronary disease but without CHF, there is net cardiac extraction 
of relaxin in contrast to reported secretion in CHF.  In patients without CHF there 
is no transpulmonary gradient in relaxin. 
 
 
 
 
 
This work has been published. 
C Fisher, S Al-Benna, A Kirk, JJ Morton, JJV McMurray. Transcardiac and 
transpulmonary gradients in the putative new cardiovascular hormone relaxin. 
Heart 2003;89:789-790. 
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CHAPTER 8: 
DISCUSSION 
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8.1 COMPARATIVE POTENCY OF RELAXIN 
 
8.1.1 Relaxin as a Systemic Vasodilator 
 
Our findings show that relaxin is a more potent arterial vasodilator than ANP, also 
secreted by the heart.  It had been suggested that relaxin might exert its systemic 
vasodilator effects by stimulating the secretion of ANP (Toth et al, 1996). 
However, our results show that relaxin is a vasodilator in its own right. 
Furthermore, relaxin is vasoactive at concentrations comparable to those found in 
CHF.  Mean plasma relaxin concentrations in patients with severe CHF average 
2.5 – 3.34 x 10 -11 M while mean plasma ANP concentrations in patients with 
severe CHF, average 2.5 x 10-11 M. At 10 -11 M, relaxin caused 26 % vasodilation 
of resistance arteries (versus 0.68 % with the same concentration of ANP).   
The potency of relaxin is impressive.  It is equipotent to epoprostenol, a substance 
regarded as a powerful vasodilator and used therapeutically in cardiovascular 
disease (Kieler-Jensen et al, 1995). Of course, epoprostenol is a particularly 
effective pulmonary vasodilator whereas relaxin seems to be devoid of this action. 
 
8.1.2 Relaxin is Endothelium Dependent 
 
We also found that relaxin induced vasodilation is endothelium dependent.  
Removal of the endothelium almost abolished its effect.  This is in keeping with 
the observation that relaxin increases nitric oxide (NO) in cultured vascular smooth 
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muscle cells from bovine aortae (Bani et al, 1998). Similarly, NO inhibition 
abolished the increase in renal plasma flow induced by relaxin in rats (Danielson, 
1999).   Relaxin also increases coronary blood flow in experimental animals 
through NO (Bani, 1997). 
 
8.1.3 Relaxin Does Not Vasodilate all Arteries. 
 
Interestingly, relaxin does not seem to vasodilate all arteries.  Human relaxin did 
not dilate human myometrial and uteroplacental arteries pre-contracted with 
norepinephrine, endothelin or U46619 (Petersen et al, 1991).  Similarly, porcine 
relaxin has no effect on human umbilical arteries pre-contracted with potassium 
chloride or serotonin (Dombrowski et al, 1986).   This suggests that relaxin does 
not act as a vasodilator in the placental-fetal circulation.  We found that relaxin is 
inert in preconstricted human pulmonary resistance arteries, in contrast to systemic 
vessels.  This may reflect differing relaxin receptor distribution in the circulation, 
as the nitric oxide vasodilator pathway was functionally intact in these pulmonary 
vessels (Bathgate et al, 2002). It should also be noted, however, that the sample of 
patients providing small pulmonary resistance arteries was small (n=5) and 2 out of 
5 patients were taking ACE inhibitors which may have influenced the overall 
result. 
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8.1.4 Other Actions of Relaxin in Cardiovascular Disease 
 
Relaxin could have other potentially favourable vascular and non-vascular actions 
in cardiovascular disease.   For example, relaxin increases vascular endothelial 
growth factor, (Unemori et al, 1999) antagonises the vasoconstrictor action of 
other peptides such as angiotensin II (Massicotte et al, 1989) and inhibits collagen 
synthesis/increases collagen breakdown (Qin et al, 1997).   The last action, key to 
the pelvic remodeling effect of relaxin, could also be important in cardiac and 
vascular remodeling.   In addition, relaxin has also been reported to protect against 
experimental ischemia-reperfusion injury (Bani 1997).   
 
Though the true vaso-regulatory role of relaxin can only be assessed using an 
antagonist, it does seem to be more potent than ANP, a hormone that circulates at a 
similar concentration and the inhibition of which leads to vasoconstriction and 
other potentially adverse cardiovascular effects (Drexler et al, 1990).  
 
8.1.5 Summary 
 
In summary, we have shown that relaxin, a hormone now known to be secreted by 
the heart, is a potent vasodilator of small systemic resistance arteries at 
pathophysiological concentrations and that this action is endothelium dependent.   
Relaxin is not, however, a pulmonary vasodilator.   The pleiotropic actions of 
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relaxin suggest that its potential role in cardiovascular regulation merits further 
investigation. 
 
 
 
 
 
8.2  THE MECHANISM OF ACTION OF RELAXIN 
 
This series of experiments, in conjunction with our prior observations, suggests 
that the vasodilator action of relaxin is endothelium-dependent in small resistance 
arteries and involves both NO-dependent and NO-independent cyclic GMP and 
prostanoid-dependent cyclic AMP second messenger pathways (though the latter 
was only clearly revealed in vessels taken from patients treated with an ACE 
inhibitor).  
 
8.2.1 In Patients Not Treated with an ACE inhibitor. 
 
In patients not treated with an ACE inhibitor, the vasodilatory action of relaxin 
appears to be mediated via the nitric oxide pathway since both L-NAME and L-
NOARG reduced relaxin’s action. In keeping with this, by blocking the 
conversion of GTP to cGMP with the guanylate cyclase inhibitor, ODQ, the 
vasodilatory action of relaxin was reduced. However, preventing the breakdown 
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of cGMP, with the cGMP phosphodiesterase inhibitor, zaprinast did not augment 
relaxin’s vasodilatory action. 
  
The Bani group in recent years has provided increasing evidence that relaxin can 
act on several of its targets by increasing the expression and/or activity of nitric 
oxide synthase (NOS) isoenzymes, thereby promoting the generation of nitric 
oxide (NO). In 1994, Masini et al, showed that the relaxin attenuated calcium 
ionophore-induced granule exocytosis by isolated rat serosal mast cells, was 
mediated by nitric oxide (Masini et al, 1994).  
 
This group then went on to show the existence of a relaxin- NO pathway causing 
increased levels of cGMP in rat and guinea pig hearts (Bani-Sacchi et al, 1995), in 
human and rabbit platelets (Bani et al, 1995a), in human breast cancer cells (Bani 
et al, 1995b) and in mouse small bowel (Bani et al, 2002). The NO synthase 
involved depends on the cell type under investigation. In the mouse uterus, relaxin 
causes up-regulation of NOS-III expression in epithelium, glands, endometrial 
stromal cells and myometrium while leaving inducible NOS (NOS II) expression 
unaffected (Bani et al, 1999). However, in rat coronary endothelial cells (Failli et 
al, 2002) and in bovine aortic smooth muscle cells (Bani et al, 1998), relaxin 
promoted expression and activity of the inducible NO synthase (NOS II) with 
negligible effects on NOS-III. 
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The protective effect of relaxin in cardiac anaphylaxis involves an up-regulation 
of the NO pathway (Ndisang et al, 2001), (Masini et al, 2002). 
 
In this group of patients, not treated with an ACE inhibitor, the prostacyclin 
pathway also appears to be important since the cyclo-oxygenase inhibitor, 
indomethacin, reduced the vasodilatory action of relaxin. As previously described, 
prostacyclin activates adenylate cyclase to produce cAMP. When we used the 
cAMP phosphodiesterase inhibitor, milrinone, to prevent cAMP breakdown, 
however, the vasodilatory action of relaxin was not augmented. The EDHF 
pathway does not appear to be important in this group of patients. 
 
 
8.2.2 In Patients Treated with an ACE inhibitor. 
 
The most surprising finding of this study was, however, that ACE inhibitor 
treatment substantially blocked the vasodilator action of relaxin (and revealed a 
second prostanoid-cAMP dependent vasodilator mechanism of action of relaxin). 
By discovering that the mechanism of action of relaxin in these patients is 
different to its action in those patients not treated with ACE inhibitors, we have 
shown that the prostacyclin pathway and the cAMP second messenger pathway 
are also important. Indomethacin blocked relaxin’s action while milrinone, by 
preventing cAMP breakdown, enhanced the vasodilatory action of relaxin in this 
group of patients.  
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The cGMP second messenger pathway may also be important in these patients. 
By blocking conversion of GTP to cGMP, ODQ reduced relaxin’s action while 
preventing cGMP breakdown with zaprinast, enhanced relaxin’s action. These 
findings were at supraphysiological levels of relaxin, however, and so may not be 
clinically relevant. 
 
Blocking the NO and EDHF pathways had a curious effect, though as rather than 
reducing the vasodilatory action of relaxin as expected, its vasodilatory effect 
was actually enhanced in patients treated with an ACE inhibitor. Again, it should 
be noted that blocking of the NO pathway causing enhancement of relaxin’s 
vasodilatory action was found at high doses i.e. supraphysiological levels of 
relaxin and so may not be clinically relevant. 
 
 
Why ACE inhibitor treatment should block the effect of relaxin is unknown and 
can only be speculated about.  Of note, the other patient characteristics in the 
ACEI treated group and the non-ACEI treated group are very similar i.e. it does 
appear to be purely an ACE inhibitor effect. ACE inhibitors do, however, up-
regulate the endothelium-vascular smooth muscle nitric oxide-cGMP pathway in 
human arteries.  If it was already substantially activated in our patients taking an 
ACE inhibitor, there may be little remaining potential for relaxin to further 
stimulate this pathway.  This circumstance may, however, have allowed 
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alternative vasodilator pathways to be revealed.  This is indeed what our studies 
with indomethacin and milrinone seem to show.  In vessels taken from patients 
treated with an ACE inhibitor, indomethacin blocked the vasodilator action of 
relaxin whereas milrinone enhanced it.  This suggests that relaxin can also act 
through a prostanoid-cAMP pathway in small human resistance arteries.  
The recent findings from PERTINENT, a substudy of the EUROPA study which 
demonstrated reduction in cardiovascular mortality and myocardial infarction in 
patients with stable coronary artery disease taking the ACEI perindopril, 
demonstrated up-regulation of the nitric oxide pathway via bradykinin (Ceconi et 
al, 2007). In this study, the effect of perindopril on endothelial function was 
determined by cultivating in vitro human umbilical vein endothelial cells 
(HUVECs). Incubation of HUVECs with serum taken at baseline from patients 
with CAD showed a significant down-regulation of endothelial nitric oxide 
synthase (eNOS) protein expression and activity (-26% and -30%, respectively; 
both p<0.01 compared with incubation with serum from the control group). At 1 
year, the down-regulation of eNOS protein expression and activity was modulated 
by the treatment with perindopril: up-regulation by 19% and 27% for eNOS 
protein expression (p=ns) and (p<0.05), respectively, was observed. This 
modulation was at least in part mediated by the activation of bradykinin B2 
receptors since the use of a specific B2 receptor antagonist, icatibant, conteracted 
the beneficial effect of perindopril. In addition, a correlation between increased 
plasma bradykinin levels and eNOS up-regulation, was noted. 
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Relaxin has previously been described to act via cAMP in animal models. 
Braddon first described relaxin-induced cAMP changes in the mouse symphysis 
in 1978 (Braddon, 1978). The causal relation between relaxin exposure, cAMP 
rise and inhibition of spontaneous contractile activity in the rat uterus was 
described back in 1980 (Sanborn et al, 1980). These observations were confirmed 
for human endometrial glandular cells (Chen et al, 1988) and human breast cells 
(Bigazzi et al, 1992). Cronin et al found that relaxin increases cAMP levels in 
cultured anterior pituitary cells (Cronin et al, 1987). Toth et al, investigated the 
effect of relaxin on the isolated perfused rat heart. A cAMP dependent protein 
kinase inhibitor (H-89) was found to substantially reduce the ANP secretory 
effect of relaxin (Toth et al, 1996). 
 
When Hsu and colleagues discovered the relaxin receptors in 2002, LGR7 and 
LGR8 (now renamed RXFP1 and RXFP2 respectively), they showed that these G 
protein coupled receptors mediate the action of relaxin through an cAMP 
dependent pathway (Hsu et al, 2002). 
 
The Ivell group suggest that activation of the relaxin receptor leads to tyrosine 
phosphorylation, which, in turn, inhibits phosphodiesterase (PDE) activity and 
further upregulates cAMP levels. They examined human endometrial stromal 
cells and human macrophages (THP-1) in the human monocyte cell line to show 
that the relaxin receptor also initiates tyrosine kinase activation (Bartsch et al, 
2001, Ivell, 2002, Bartsch et al, 2004, Ivell et al, 2005).  
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Previously we showed that endothelial denudation greatly reduced the 
vasodilation action of relaxin in human small resistance arteries.  This observation 
was in keeping with a number of animal studies and a study in human vascular 
smooth muscle cells suggesting the action of relaxin involves nitric oxide-cGMP 
signalling.  In spite of this, neither inhibition of nitric oxide synthase with L-
NOARG, or with L-NAME, blocked the vasodilator effect of relaxin in this study, 
in patients treated with ACE inhibitors.  Direct inhibition of soluble guanylate 
cyclase with ODQ did, however, reduce the vasodilator action of relaxin, raising 
the possibility that relaxin causes NO-independent activation of soluble guanylate 
cyclase in these patients.  In keeping with this, the cGMP phosphodiesterase 
inhibitor zaprinast, which prevents the breakdown of cGMP, augmented the 
vasodilator effect of relaxin.   
 
Other groups have demonstrated that relaxin’s vasodilatory effect is mediated via 
more than one distinct pathway. Longo et al, studied uterine arteries from 
pregnant rats and found that relaxin’s effect in these arteries was mediated by 
nitric oxide, soluble guanylate cyclase (which converts GTP to cGMP) and 
adenylate cyclase (which is responsible for the production of cAMP). They 
suggest that the NO-cGMP pathway is one of the second messenger systems 
involved in the vascular effects of relaxin in pregnancy but that cAMP is also 
involved (Longo et al, 2003). 
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Putative interactions between relaxin receptor signaling and the intrinsic NO 
pathway have been described (Nistri and Bani, 2003). See Figure 8.1 below. 
 
 
Figure 8.1  Possible Interactions Between Relaxin Receptor and NO 
Pathway. 
 
 
 
 
 
 
 
 
 
 
 
AC: adenylate cyclase, cAMP: cyclic adenosine monophosphate, cGMP: cyclic 
guanosine monophosphate, GC: guanylate cyclase, Gs: Gs proteins, GTP: 
guanosine triphosphate, IκB: inhibitor subunit of nuclear factor kappa-B, PKA: 
AC 
Gs 
NF-κB 
NOS II PKA 
GTP cGMP 
GC 
nucleus 
IκB 
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NO cAMP 
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protein kinase,  NF-κB: nuclear factor kappa-B, NO: nitric oxide, NOS II: 
inducible NO synthase, NOS III: constitutive NO synthase, RLX: relaxin 
(Adapted from Nistri and Bani, 2003). 
 
 
 
Our studies have, however, by necessity been carried out in arteries from patients 
with coronary heart disease and it is possible that the balance between these 
vasodilator mechanisms could be different in healthy controls.  Coats et al, 
showed that EDHF is the major contibutor to endothelium-dependent 
vasorelaxation in human subcutaneous resistance arteries in healthy volunteers 
(Coats et al, 2001). We have been unable to confirm this as a mechanism of 
action for relaxin, in resistance arteries taken from patients with coronary artery 
disease. 
From a therapeutic perspective, however, our patient group is relevant and 
interesting.  The therapeutic potential of relaxin as a vasodilator is perhaps less 
than previously considered, given that so many patients with cardiac disease have 
an indication for treatment with an ACE inhibitor.   
 
Our results, however, open up another possible therapeutic avenue for relaxin.  
Type 5 phosphodiesterase inhibitors seem to have limited effectiveness as a 
treatment for erectile dysfunction in certain subsets of patients, for example 
diabetics, probably because of impaired endogenous NO production.  
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Theoretically, NO-independent activators of guanylate cyclase (of which relaxin 
seems to be one) may be more effective. 
 
 
 
8.2.3 Summary 
 
In summary, we have shown that the vasodilator peptide relaxin acts differently in 
human small resistance arteries in patients treated and not treated with ACE 
inhibitors. In ACEI-treated patients, relaxin appears to work via two distinct 
second messenger systems.  One pathway involves vasodilator prostanoids and 
cAMP. The other pathway may involve NO-independent activation of guanylate 
cyclase and cGMP.  
 
In non-ACEI-treated patients, relaxin works via an NO-dependent cGMP second 
messenger pathway. The other pathway involves vasodilator prostanoids but this 
does not appear to be as powerful as the cGMP pathway. 
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8.3 RELAXIN IN HUMAN INTERNAL MAMMARY ARTERIES AND 
SAPHENOUS VEINS 
 
Although, in small human systemic resistance arteries, we showed that relaxin is a 
potent vasodilator (Fisher et al, 2002), we were unable to find that in human large 
calibre vessels i.e. internal mammary arteries and long saphenous veins that relaxin 
had any vasodilator effect compared to control. 
 
8.3.1 Relaxin is Endothlium-Dependent 
 
We know that relaxin is endothelium-dependent and it proved to be extremely 
difficult to obtain samples of IMA and LSV where the endothelium was indeed 
intact. Although for this set of experiments, only vessels where the endothelium 
had been found to be intact, were used in the data set, perhaps the endothelial 
function of the vessels was impaired and this had an impact with regard to 
relaxin’s lack of action. Of course, relaxin may not act as a vasodilator of large 
calibre vessels and certainly Reid et al, reported that relaxin had no effect on 
endothelium intact rat aortae pre-constricted with noradrenaline (Reid et al, 2001). 
Of course, there may also be marked species differences in the action of relaxin as 
documented with other peptides. Interestingly, Hillier et al, investigated the action 
in humans, of the peptide, human urotensin II (hUII) which is a potent 
vasoconstrictor in some fish and mammals (e.g. cynomolgus monkey). They found 
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that hUII had no vasoconstrictor action in human arteries and veins of different 
sizes and vascular beds showing a marked species difference (Hillier et al, 2001b). 
 
 
8.3.2 Relaxin and Arteries 
 
It would seem, therefore, that relaxin does not vasodilate all arteries.  Human 
relaxin did not dilate human myometrial and uteroplacental arteries pre-contracted 
with norepinephrine, endothelin or U46619 (Petersen et al, 1991).  Similarly, 
porcine relaxin has no effect on human umbilical arteries pre-contracted with 
potassium chloride or serotonin (Dombrowski et al, 1986).   This suggests that 
relaxin does not act as a vasodilator in the placental-fetal circulation.  We found 
that relaxin is inert in preconstricted human pulmonary resistance arteries, in 
contrast to systemic vessels (Fisher et al, 2002).  This may reflect differing relaxin 
receptor distribution in the circulation, as the nitric oxide vasodilator pathway was 
functionally intact in these pulmonary vessels (Bathgate et al, 2002). 
 
8.3.3. Relaxin and Veins 
 
There is very little reported in the literature regarding the action of relaxin on the 
venous system. Massicotte et al, found that there was a blunted response to 
vasoconstrictors, arginine-vasopressin and norepinephrine in the perfused 
mesenteric artery (with the concentration response curves shifted to the right by a 
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factor of two (p<0.05 and p<0.005 respectively) after treatment with relaxin. 
However, in the isolated portal vein, no statistical differences were observed in 
either the maximum response or sensitivity to angiotensin II or norepinephrine 
(Massicotte et al, 1989). 
 
8.3.4 Relaxin and ACE Inhibitors 
 
We reported that the vasodilatory effect of relaxin in patients treated with ACE 
inhibitors is significantly reduced. Of the ten patients whose IMA and LSV were 
harvested at the time of coronary artery bypass grafting, only 2 of them were on 
ACE inhibitors, so this is unlikely to be the cause of relaxin’s lack of effect in IMA 
and LSV.   
 
8.3.5 Relaxin and Beta-blockers 
 
There has been very little reported in the literature on the interaction of 
betablockers with relaxin. One in vivo study reported that treatment with the β-
adrenoreceptor antagonist propanolol significantly reduces the heart rate response 
to relaxin (Summerlee and Parry, 1993). In in vitro studies, propanolol has a small 
inhibitory action on the effects of relaxin in the heart (Kakouris et al, 1992). Of the 
10 patients whose IMA and LSV were used in the study, 8 of them were on beta-
blockers so this may have had an effect on relaxin in these vessels. Against this 
hypothesis however, is the fact that in our study on small resistance arteries where 
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relaxin was found to be a potent vasodilator, 11 out of 13 patients were on long 
term betablockers.  
 
 
8.3.6 Summary 
 
We have been unable to show that relaxin has a vasodilatory effect in human large 
calibre vessels, neither internal mammary arteries nor long saphenous veins. 
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8.4 RELAXIN COMPARED WITH NT pro BNP AS A PROGNOSTIC 
INDICATOR IN HEART FAILURE 
 
Our study confirms that heart failure due to left ventricular systolic dysfunction is 
associated with marked elevation of the plasma concentration of the two new 
neurohumoral markers N-terminal pro BNP and relaxin.   
 
8.4.1 NT pro BNP in Heart Failure 
 
Prior to this study, there were few reports of plasma NT pro BNP levels in heart 
failure. Hobbs et al, investigated the performance of NT pro BNP in diagnosing 
heart failure in various randomly selected general and high risk community 
populations. They found that for NT pro BNP in the diagnosis of heart failure in 
the general population, a level of >36 pmol/l had a sensitivity of 100%, a 
specificity of 70%, a positive predictive value of 7% and a negative predictive 
value of 100% (Hobbs et al, 2002). Masson et al compared BNP with NT pro BNP 
in ambulatory patients with heart failure and found that the concentration of both 
peptides increased in a similar fashion according to the severity of NYHA class, 
left ventricular ejection fraction, aetiology and age. They concluded that NT pro 
BNP correlates equally to BNP with clinical variables in patients with CHF. Hunt 
et al, also compared BNP with NT pro BNP in patients with heart failure. They 
noted that plasma levels of NT pro BNP are raised in cardiac impairment, 
including NYHA class I i.e. asymptomatic patients, and rise with cardiac 
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decompensation. They found that the proportional and absolute increment above 
normal levels of NT pro BNP exceeds that for BNP suggesting that NT pro BNP 
may be a more discerning marker of early cardiac dysfunction than BNP (Hunt et 
al, 1997). Talwar et al, found that NT pro BNP is a strong, independent predictor 
of left ventricular dysfunction demonstrating a linear relationship between NT pro 
BNP and left ventricular wall motion index. NT pro BNP had a sensitivity of 95% 
and specificity of 55%. Of more clinical importance, they felt, was the high 
negative predictive value of 93% of NT pro BNP in the diagnosis of left 
ventricular dysfunction (Talwar et al,1999). 
 
 
8.4.2 Relaxin in Heart Failure 
 
At the time of this study, there was only one other report describing relaxin 
concentrations in heart failure (Dschietzig et al, 2001).  
 
More recently, Kupari et al, investigated the role of relaxin in pressure overload-
induced human heart failure. They studied patients undergoing cardiac 
catheterisation for isolated aortic stenosis. Blood was sampled from the aortic root 
and from the coronary sinus. The concentration gradients of relaxin from the aortic 
root to the coronary sinus indicated relaxin extraction by the heart in control 
patients in keeping with the findings from our study (Fisher et al, 2003a) described 
in Chapter 7. In patients with systolic heart failure the transcardiac gradient 
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indicated relaxin production. However, this did not translate into elevated systemic 
concentrations. They conclude that relaxin is not a major player in human heart 
failure (Kupari et al, 2005). Kruger et al, investigated circulating relaxin and its 
potential role in stable CHF at rest and after physical exercise. They were unable to 
find a difference in relaxin plasma levels at rest and after exercise between patients 
with CHF and controls (Kruger et al, 2004). 
 
8.4.3 NT pro BNP as a Predictor of Outcome. 
 
In this study, NT pro BNP was also predictive of both death and death or 
readmission with worsening CHF.  Though the predictive value of other natriuretic 
peptides in CHF has been extensively reported (Hall, 1994), (Eriksson, 1995), 
(Dickstein, 1997), (Selvais, 2000), (McDonagh, 2001), (Bettenscourt, 2002), we 
know of only one other study (at the time of this study) describing the prognostic 
importance of NT pro BNP in CHF (Richards, 2001).  In a sub-study of the 
Australia New Zealand carvedilol trial, Richards et al found that NT pro BNP was 
a strong predictor of all cause mortality as well as admission to hospital with CHF.  
In that study, NT pro BNP had more predictive power for these outcomes than left 
ventricular ejection fraction.  We also found NT-pro BNP to be an independent 
predictor of adverse clinical outcome.  Consequently, there are now two studies 
confirming that this very stable peptide (Hughes et al, 1999), (Downie et al, 1999), 
which is easy to assay (Hunt et al, 1997), (Hughes et al, 1999), (Downie et al, 
1999), has prognostic as well as diagnostic value in CHF.  Since publishing our 
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data (Fisher et al, 2003b), there have been numerous studies published showing the 
predictive value of NT pro BNP in heart failure prognosis (Hartmann et al, 2004), 
(Groenning et al, 2004), (Kirk et al, 2004), (Squire et al, 2004). 
 
NT pro BNP also gives prognostic information after myocardial infarction and in 
acute coronary syndromes (Richards et al, 1998), (Omland et al, 2002). Richards et 
al, found that plasma NT pro BNP levels measured 2 to 4 days after myocardial 
infarction independently predicted left ventricular function and 2-year survival. 
They conclude that stratification of patients into low and high risk groups could be 
facilitated by NT pro BNP measurements. 
 
Recently, NT pro BNP has been shown to be an independent prognostic marker in 
severe sepsis and septic shock (Varpula et al, 2007); infective endocarditis 
(Kahveci et al, 2007); after vascular surgery (Mahla et al, 2007) and in stable 
coronary artery disease (Omland et al, 2007). 
 
8.4.4 Summary 
 
Dschietzig et al have recently shown that cardiac relaxin production and plasma 
relaxin concentrations are increased in CHF, the latter finding confirmed in the 
present study (Dschietzig et al, 2001).  As relaxin is a powerful vasodilator 
secreted by the heart (Fisher et al, 2002), our hypothesis was that like the 
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natriuretic peptides, plasma concentrations might be related to prognosis.  We were 
not able to confirm this. 
The timing of blood samples may be relevant. Blood samples were taken from 
CHF patients prior to discharge i.e. once stable. Perhaps if the sampling had been 
done on admission (when the patient was in acute heart failure) we may have been 
able to show relaxin concentrations related to prognosis. 
Though plasma concentrations of most neurohumoral factors are predictive of 
outcome, not all are (e.g. arginine vasopressin) (Richards et al, 1998).  We were 
unable to show any correlation between plasma NT pro BNP and relaxin 
concentrations suggesting different release mechanisms.  The atria may be a more 
important source of relaxin than the ventricles, whereas the opposite is true for NT 
pro BNP (Dschietzig et al, 2001), (Taylor et al, 1994).  As a biochemical marker of 
left ventricular dilatation and wall stress, it is perhaps not surprising, therefore, that 
NT pro BNP is a powerful prognostic factor (Richards et al, 2001).  Furthermore, 
net cardiac relaxin release is not pronounced except in moderate to severe CHF and 
even then is not always observed.  These reasons may explain why relaxin was not 
predictive of outcome.  However, it remains possible that relaxin does have some 
weak predictive effect which was not revealed because of the modest size of our 
study.  
 
In summary, even though relaxin has been shown to be a potent vasodilator 
released by the failing heart, it is not a powerful prognostic indicator in CHF. 
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8.5 TRANSCARDIAC AND TRANSPULMONARY GRADIENTS OF 
RELAXIN 
 
Dschietzig et al showed higher coronary sinus than left ventricular relaxin 
concentrations in 11 of 14 patients with severe CHF, suggesting that the failing 
heart may be a source of circulating relaxin (Dschietzig et al, 2001).  We found the 
opposite across the non-failing heart i.e. net extraction of relaxin. Kupari et al, have 
since confirmed this finding in patients without heart failure (Kupari et al, 2005). 
Further inspection of the data from Dschietzig et al shows no trans-cardiac gradient 
in patients with moderate CHF and an aorta-coronary sinus decrement in controls, 
in keeping with our findings (Dschietzig et al, 2001).  This suggests that the 
contribution of the heart to circulating relaxin varies according to the presence or 
absence of CHF.  Whether it is left ventricular systolic dysfunction, abnormal 
pulmonary or systemic haemodynamics, neurohumoral activation or other factors 
that leads to net cardiac secretion of relaxin in CHF is presently unknown.  
 
The pattern of relaxin secretion/extraction is distinct from other hormones.  A-type 
and B-type natriuretic peptide increase from aorta to coronary sinus in both the 
non-failing and failing heart (more markedly in the latter) (Northridge et al, 1992). 
Adrenomedullin is also secreted by both the failing and non-failing heart. In 
contrast, endothelin-1 is extracted by the failing heart, whereas there seems to be 
either no trans-cardiac gradient or higher coronary sinus concentrations in non-
failing hearts (Stangl et al, 2000). There is no trans-cardiac gradient in plasma 
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aldosterone concentration in the non-failing heart but an increment in coronary 
sinus aldosterone concentration in CHF. 
 
Interpretation of the cardiac extraction of relaxin by the normal heart, compared to 
its secretion by the failing heart, is difficult.  The mechanisms of relaxin clearance 
from the circulation are unknown.  Changes in the trans-cardiac concentration of 
other peptides seem to reflect changes in receptor density/affinity e.g. decreases in 
endothelin concentration across the failing heart are probably caused by the 
increase in myocardial ETA and ETB (Stangl et al, 2000).  The receptors for relaxin 
have only recently been described and nothing is known about the effect of CHF on 
their expression (Dschietzig et al, 2001). 
 
The transpulmonary gradient in relaxin concentration has not been described 
before.  Neither net extraction nor secretion occurred, which is different than for 
other peptides.  Pulmonary extraction of ANP (Northridge et al, 1992) and 
adrenomedullin has been described.  For endothelin, some have described no 
transpulmonary concentration gradient, others pulmonary extraction and others still 
that both secretion and extraction, which balance each other out, occur (Stangl et al, 
2000).  Relaxin also differs from other peptides in having no effect in small 
pulmonary resistance arteries (whereas it is a potent vasodilator in comparable 
vessels from the systemic circulation) (Fisher et al, 2002). 
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In summary, in patients with coronary disease but without CHF, there is net cardiac 
extraction of relaxin in contrast to reported secretion in CHF.  In patients without 
CHF there is no transpulmonary gradient in relaxin. 
 
 
 
8.6 LIMITATIONS OF RESEARCH 
 
8.6.1 Subjects studied 
 
On determining the comparative potency of relaxin and its mechanism of action, 
patients with coronary artery disease generously provided buttock biopsies as a 
source of small resistance arteries. In addition to this, it would have been useful to 
have had similar samples from healthy volunteers to determine the comparative 
potency and mechanism of action of relaxin in these subjects. 
Also, the patients that had buttock biopsies taken, had coronary artery disease but 
were not known to have heart failure and it would have been interesting to see if 
relaxin’s comparative potency and mechanism of action differs in patients with 
heart failure. 
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8.6.2 In Vivo Studies 
 
We had hoped as part of my MD thesis to perform in vivo studies of the action of 
relaxin in human resistance arteries with plasma concentrations reflecting the 
physiological and pathophysiological range. This would have involved 1) dorsal 
hand vein studies, using a modified Aellig technique, to document the local effect 
of relaxin in a human dorsal hand vein and 2) forearm venous occlusion 
plethysmography to study the local arterial effect of relaxin in the human brachial 
artery. 
Unfortunately, Connectics Corporation who kindly gifted the relaxin for use in my 
ex vivo experiments, would not allow in vivo studies using relaxin gifted by them to 
be performed in humans. 
 
 
 
8.7 FUTURE RESEARCH 
 
The field of relaxin research is progressing rapidly. A single site open-label study 
of relaxin in patients with compensated CHF has recently been completed in 
Germany (Dschietzig et al, 2009). This was a safety and dose-finding study of 
intravenous relaxin given for 24 hours at doses ranging from 10 to 960 µg/kg/day. 
Pharmacodynamic dose-response parameters (serial haemodynamic measurements 
using pulmonary artery and radial artery catheters and serial renal chemistry 
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parameters) were evaluated to define relaxin doses for further study. The study 
enrolled 16 subjects with compensated CHF, NYHA class II-III due to ischaemic 
heart disease, hypertensive heart disease or dilated cardiomyopathy with keft 
ventricular ejection fraction <35%, pulmonary capillary wedge pressure (PCWP) > 
16mmHg and cardiac index <  2.5 l/min/m2. All 16 subjects completed dosing and 
the day 9 follow-up visit. Relaxin was safe and well-tolerated in all subjects. Doses 
of relaxin in the range of 10-100 µg/kg/day appeared to have a more pronounced 
effect than higher doses on right atrial pressure, pulmonary artery pressure, PCWP 
and NT pro-BNP while higher doses in the range of 240-960 µg/kg/day tended to 
have a greater effect on CI. Values for systemic vascular resistance decreased at all 
doses. The different dose responses observed may be explained by imbalances in 
baseline haemodynamic status of the dose groups or may be due to random 
variability in a small pilot study. However, the effect of relaxin may follow a U-
shaped dose-response curve.  
A high proportion of patients with acute heart failure have elevated blood pressure 
at the time of presentation, so called acute vascular failure (Teichman et al, 2008). 
Renal dysfunction is a common co-morbidity and major predictor of poor outcomes 
in patients with acute heart failure and appears to be particularly common in 
patients with acute vascular failure. Currently, no therapy has been demonstrated to 
improve symptoms or renal function in this group of patients. The current 
understanding of the haemodynamic and renovascular effects of relaxin, as well as 
the encouraging results from the evaluation of relaxin in patients with compensated 
heart failure, support the investigation of the use of relaxin as a therapeutic agent 
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for the treatment of patients with acute vascular failure. The RELAX-AHF study 
has been undertaken to evaluate the effects of relaxin therapy on symptoms, signs 
and outcomes in these patients and its results are eagerly awaited. 
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